<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Venlafaxine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Venlafaxine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Venlafaxine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11141" href="/d/html/11141.html" rel="external">see "Venlafaxine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12878" href="/d/html/12878.html" rel="external">see "Venlafaxine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5710003"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Venlafaxine is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233762"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Effexor XR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868587"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Venlafaxine XR;</li>
<li>APO-Venlafaxine XR;</li>
<li>Auro-Venlafaxine XR;</li>
<li>Effexor XR;</li>
<li>M-Venlafaxine XR;</li>
<li>PMS-Venlafaxine XR;</li>
<li>PMSC-Venlafaxine XR;</li>
<li>SANDOZ Venlafaxine XR;</li>
<li>TARO-Venlafaxine XR;</li>
<li>TEVA-Venlafaxine XR;</li>
<li>Venlafaxine XR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F233802"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F233767"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder:</b>
<b>Oral:</b>
<b>Note:</b> Do not initiate therapy, titrate by doses &lt;112.5 mg, or taper treatment with ER besylate tablets. Use other ER products to initiate, titrate, administer doses &lt;112.5 mg/day, and to taper during discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER besylate:</i> Initial: 112.5 mg once daily in patients who have received ≥75 mg/day of another venlafaxine ER product for at least 4 days; may then be increased by ≤75 mg/day increments (using another venlafaxine ER product) at intervals ≥4 days as tolerated (maximum dose: 225 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER hydrochloride: </i>Initial: 37.5 to 75 mg once daily; in patients who are initiated at 37.5 mg once daily, increase to 75 mg once daily after 4 to 7 days; may then be increased by ≤75 mg/day increments at intervals of ≥4 days as tolerated; usual dosage: 75 to 225 mg once daily (maximum dose: 225 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<b>Oral: Note:</b> Do not initiate therapy, titrate by doses &lt;112.5 mg, or taper treatment with ER besylate tablets. Use other ER products to initiate, titrate, administer doses &lt;112.5 mg/day, and to taper during discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER besylate:</i> Initial: 112.5 mg once daily in patients who have received ≥75 mg/day of another venlafaxine ER product for at least 4 days; may then be increased by ≤75 mg/day increments (using another venlafaxine ER product) at intervals ≥4 days as tolerated (maximum dose: 225 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ER hydrochloride:</i> Initial: 37.5 to 75 mg once daily; in patients who are initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4 to 7 days; thereafter, may increase dose in increments of ≤75 mg/day at intervals of ≥4 days based on response and tolerability (slower intervals of every 2 to 4 weeks are appropriate in less clinically urgent situations); usual dosage: 75 to 225 mg once daily (manufacturer's maximum dose: 225 mg/day; guidelines support doses of up to 375 mg/day based on limited experience) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>). Some experts use more rapid titrations (every 2 to 3 days) in combination with an antipsychotic (eg, quetiapine) for patients with psychotic features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19694628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19694628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Im</i>
<i>mediate release:</i> Initial: 37.5 to 75 mg/day; daily doses &gt;37.5 mg are administered in 2 or 3 divided doses; may increase dose in increments of ≤75 mg/day at intervals of ≥4 days based on response and tolerability (slower intervals of every 2 to 4 weeks are appropriate in less clinically urgent situations); usual dosage: 75 to 375 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>) (maximum dose: 375 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b>
<i>ER hydrochloride</i>: Initial: 37.5 mg once daily for 1 week; may increase based on response and tolerability by 37.5 mg increments at weekly intervals to a target dose of 75 to 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22683887','lexi-content-ref-15705120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22683887','lexi-content-ref-15705120'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4954632d-5953-4cb6-abb9-037352ab5f57">Narcolepsy with cataplexy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy with cataplexy (off-label use):</b> Limited data available: <b>Oral:</b>
<i>IR and ER hydrochloride:</i> Some experts suggest doses of 37.5 to 75 mg twice daily (immediate release) or 37.5 to 150 mg once daily (ER hydrochloride). Initiate at a low dose and gradually increase based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Scammell.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Scammell.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59556411-2ce5-4b81-a269-2440b011fcb2">Neuropathic pain associated with diabetes mellitus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuropathic pain associated with diabetes mellitus (off-label use): Oral:</b>
<i>ER hydrochloride</i>: Initial: 37.5 mg or 75 mg once daily; increase by 75 mg each week to a maximum dosage of 225 mg once daily based on tolerance and effect. An adequate duration to determine effect and to accomplish titration has been documented to be 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21482920','lexi-content-ref-18413214','lexi-content-ref-15288411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21482920','lexi-content-ref-18413214','lexi-content-ref-15288411'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (alternative agent) (off-label use): Note:</b> Alternative for patients with limited or no response to SSRI therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849776'])">Ref</a></span>). <b>Oral:</b>
<i>IR and ER hydrochloride</i>: Initial: 75 mg once daily for ER hydrochloride or 75 mg/day in 3 divided doses for immediate release; increase in increments of 75 mg every 2 weeks to 225 mg/day. Increase further based on response and tolerability up to 350 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12444814','lexi-content-ref-17849776','lexi-content-ref-14624187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12444814','lexi-content-ref-17849776','lexi-content-ref-14624187'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder:</b>
<b>Oral:</b>
<i>ER hydrochloride:</i> Initial: 37.5 mg once daily for 1 week; may increase to 75 mg once daily after 7 days, may then be increased by ≤75 mg/day increments at intervals of ≥7 days; usual dosage: 75 to 225 mg once daily (maximum dose: 225 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (off-label use):</b>
<b>Oral:</b>
<i>ER hydrochloride</i>: Initial: 37.5 mg once daily; increase based on response and tolerability by ≤75 mg/day increments at intervals of ≥4 days up to 300 mg once daily. Average doses in clinical trials were ~170 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17015818','lexi-content-ref-16702890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17015818','lexi-content-ref-16702890'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c36dd6b3-72d8-44c0-9113-9b954af8885b">Premenstrual dysphoric disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder (alternative agent) (off-label use):</b>
<i>Continuous daily dosing regimen</i>: <b>Oral:</b>
<i>ER hydrochloride</i>: Based on limited data, some experts suggest 37.5 mg once daily initially; over the first month, increase to a usual effective dose of 75 mg once daily; in subsequent menstrual cycles, further increases in dose (eg, in 37.5 mg increments per menstrual cycle) up to 150 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder: Oral:</b>
<i>ER hydrochloride:</i> Initial: 37.5 mg once daily; increase to 75 mg/day after 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2018'])">Ref</a></span>). May continue to increase in increments of 75 mg each week based on response and tolerability up to 225 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15699296','lexi-content-ref-24399428','lexi-content-ref-15258718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15699296','lexi-content-ref-24399428','lexi-content-ref-15258718'])">Ref</a></span>); however, doses &gt;75 mg/day have demonstrated greater adverse effects and without greater efficacy. Manufacturer’s labeling: Dosing in the prescribing information may not reflect current clinical practice: Initial and maximum dose: 75 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent) (off-label use): Note:</b> Alternative for patients unable or unwilling to take estrogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22193145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22193145'])">Ref</a></span>). <b>Oral:</b>
<i>IR and ER hydrochloride</i>: Initial: 37.5 mg once daily; may increase dose after ≥1 week based on response and tolerability to 75 mg once daily for ER hydrochloride or 75 mg/day in 2 to 3 divided doses for immediate release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22193145','lexi-content-ref-15625158','lexi-content-ref-17229772','lexi-content-ref-11145492','lexi-content-ref-16505409','lexi-content-ref-26382310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22193145','lexi-content-ref-15625158','lexi-content-ref-17229772','lexi-content-ref-11145492','lexi-content-ref-16505409','lexi-content-ref-26382310'])">Ref</a></span>). <b>Note:</b> Doses up to 150 mg/day have been evaluated; however, compared to 75 mg/day, there was no greater efficacy and adverse effects were increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11145492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11145492'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Dosing conversion:</i></b> Patients treated with a therapeutic dose with venlafaxine immediate release may be switched to venlafaxine ER besylate at the nearest equivalent dose (mg/day) if the total dosage is either 112.5 mg/day or 225 mg/day or venlafaxine ER hydrochloride at the nearest equivalent dose (mg/day). Following the formulation switch, individual dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Due to its short half-life, withdrawal symptoms are possible after abrupt discontinuation; consider tapering to avoid withdrawal and assess for symptom recurrence. When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). The ER besylate tablet should not be used for tapering because the dosage strengths are not available below 112.5 mg. Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Switching antidepressants: </i></b>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of venlafaxine.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 7 days to elapse between discontinuing venlafaxine and initiation of an MAOI according to manufacturer labeling; however, experts recommend a 14-day washout period before initiating an MAOI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990443"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b> Oral: </b>Immediate release and extended release:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<b>Altered kidney impairment </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-8033490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-8033490'])">Ref</a></span>)<b>:</b></b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Initial: 37.5 mg once daily; titrate cautiously, not to exceed 50% of the maximum recommended dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>The manufacturer recommends a 25% dose reduction in patients with CrCl 10 to 70 mL/minute (immediate release), a 25% to 50% reduction with CrCl 30 to 89 mL/minute (extended release), and a ≥50% reduction with CrCl &lt;30 mL/minute (extended release), and the maximum recommended dose of venlafaxine ER besylate is 112.5 mg/day; however, due to high individual variability, the decrease in clearance of venlafaxine and its metabolite is only evident in subjects with CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8033490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8033490'])">Ref</a></span>); doses in patients with higher CrCls should be individualized based on efficacy and tolerability.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (venlafaxine and active metabolite, O-desmethylvenlafaxine); clearance of venlafaxine and O-desmethylvenlafaxine is reduced ~56% with high interpatient variability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8033490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8033490'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 37.5 mg once daily; titrate cautiously, not to exceed 50% of the maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-8033490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-8033490'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>The manufacturer recommends a ≥50% dose reduction of ER capsules and tablets in patients undergoing hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are unlikely to be dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 37.5 mg once daily; titrate cautiously, not to exceed 50% of the recommended maximum dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: </b>Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are unlikely to be removed by CRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 37.5 mg once daily; titrate cautiously, not to exceed 50% of the maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are unlikely to be removed by PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 37.5 mg once daily; titrate cautiously, not to exceed 50% of the maximum recommended dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987637"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A and B): Reduce total daily dose by 50%. There is variability in clearance for patients with cirrhosis; therefore, a reduction in total daily dose of more than 50% may be necessary. The maximum recommended dose of venlafaxine ER besylate is 112.5 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling; however, a reduction in total daily dose of at least 50% or more is prudent in patients with cirrhosis. The maximum recommended dose of venlafaxine ER besylate is 112.5 mg/day.</p></div>
<div class="block doe drugH1Div" id="F233768"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. No specific recommendations for elderly; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antidepressants:</b></i> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F2237702"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12878" href="/d/html/12878.html" rel="external">see "Venlafaxine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Venlafaxine extended release is available in 2 different formulations: Hydrochloride salt (eg, Effexor XR) and besylate 24-hour tablet; use caution to ensure appropriate dosage form.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available; efficacy results variable: <b>Note:</b> Not recommended as first or second-line therapy in the management of ADHD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31570648','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31570648','lexi-content-ref-NICE.1'])">Ref</a></span>); venlafaxine has shown minor positive benefits for some outcomes in small trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17822339','lexi-content-ref-9231317','lexi-content-ref-20860068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17822339','lexi-content-ref-9231317','lexi-content-ref-20860068'])">Ref</a></span>); robust evidence is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents &lt;17 years: Oral: Immediate release: Initial: 12.5 to 25 mg once daily for 1 week, then increase by 12.5 to 25 mg/day increments at weekly intervals based on response and tolerability to a weight-based maximum daily dose: Weight &lt;30 kg: 50 mg/<b>day</b> in 2 divided doses; weight ≥30 kg: 75 mg/<b>day</b> in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9231317','lexi-content-ref-20860068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9231317','lexi-content-ref-20860068'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d02be2f-b5db-4b86-bd90-9894c87082f8">Generalized anxiety disorder, social anxiety, separation anxiety, or panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder, social anxiety, separation anxiety, or panic disorder:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In pediatric patients, selective serotonin-norepinephrine reuptake inhibitor (SNRI) therapy may be considered a pharmacologic treatment option (not first-line) for moderate to severe anxiety disorders, ideally in combination with cognitive behavioral therapy (CBT); of the SNRIs with positive pediatric data evaluated in the AHRQ/Mayo review (ie, venlafaxine, duloxetine), a preferred SNRI has not been defined, although duloxetine does have FDA approval for this indication in pediatric patients ≥7 years of age. Therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401','lexi-content-ref-26126579','lexi-content-ref-29099547','lexi-content-ref-26660158','lexi-content-ref-25449861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401','lexi-content-ref-26126579','lexi-content-ref-29099547','lexi-content-ref-26660158','lexi-content-ref-25449861'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Extended-release capsule (hydrochloride salt; eg, Effexor XR): Initial: 37.5 mg once daily for 1 week, then titrate slowly according to patient weight, available dosage form strengths, response, and tolerability (see the following table) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17267793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17267793'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Weight (kg)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Week 2</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Week 3 to 4 </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Week 4 to 8</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">25 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;">37.5 mg or 75 mg</p></td>
<td align="left">
<p style="text-indent:0em;">37.5 mg or 75 mg</p></td>
<td align="left">
<p style="text-indent:0em;">37.5 mg, 75 mg, or 112.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to &lt;50 kg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg or 112.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg, 112.5 mg, or 150 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥50 kg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg or 150 mg</p></td>
<td align="left">
<p style="text-indent:0em;">75 mg, 150 mg, or 225 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on 2 randomized, double-blind, placebo-controlled trials which showed, in the initial trial, statistically significant greater improvement in primary outcome and some secondary outcome measures compared to placebo; in the second trial, although not significant, improvement in primary outcome measures were reported and the secondary outcome showed statistically significant greater improvement than placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17267793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17267793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of depression in children and adolescents, if pharmacotherapy is deemed necessary with/without cognitive behavioral therapy (CBT), a selective serotonin reuptake inhibitor (SSRI) is recommended as first-line pharmacologic therapy; an SNRI, like venlafaxine, may be considered in SSRI-refractory cases with CBT; patients should be closely monitored for adverse effects (suicidal ideation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30063169','lexi-content-ref-NICE.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30063169','lexi-content-ref-NICE.3'])">Ref</a></span>). Therapy should be initiated at a low dose and titrated every 1 to 2 weeks based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-30397569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-30397569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Extended-release capsule (hydrochloride salt; eg, Effexor XR): Initial: 37.5 mg once daily for week 1, then titrate with once-daily dosing by the following: Increase to 75 mg/day for week 2; increase to 112.5 mg/day for week 3; increase to 150 mg/day for weeks 4 to 6; if no response after week 6, may further increase to 225 mg/day. Dosing based on the Treatment of Resistant Depression in Adolescents (TORDIA) regimen which evaluated 166 patients 12 to 18 years of age with SSRI-resistant major depressive disorder who were switched to venlafaxine with or without CBT; results showed greater response when venlafaxine combined with CBT versus medication only (54.8% versus 40.5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18314433','lexi-content-ref-20478877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18314433','lexi-content-ref-20478877'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI or SNRI before adding the new antidepressant) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SNRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193360"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51193361"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block arsc drugH1Div" id="F54505383"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21407889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21407889'])">Ref</a></span>). Treatment-emergent mania or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) has been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-18837867','lexi-content-ref-15362257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-18837867','lexi-content-ref-15362257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonergic antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-29536379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-29536379'])">Ref</a></span>), although prospective studies have not determined if the cause of the increased risk of bleeding is due to SSRI use alone. For SNRIs, less data exist compared to SSRIs and data supporting an association with bleeding are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-26579809','lexi-content-ref-22285303','lexi-content-ref-26264066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-26579809','lexi-content-ref-22285303','lexi-content-ref-26264066'])">Ref</a></span>). However, there are case reports of <b>bruises</b>, <b>ecchymoses</b>, <b>gingival hemorrhage</b>, and <b>vaginal </b>
<b>hemorrhage </b>associated with venlafaxine and some observational studies have observed an increased risk for<b> postpartum hemorrhage </b>(exposure during late gestation), stroke, and <b>gastrointestinal hemorrhage </b>in patients receiving SNRIs, predominately with studies using venlafaxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27722026','lexi-content-ref-26855096','lexi-content-ref-32075794','lexi-content-ref-27637098','lexi-content-ref-9040933','lexi-content-ref-28383363','lexi-content-ref-18188866','lexi-content-ref-12013367','lexi-content-ref-31635997','lexi-content-ref-18460039','lexi-content-ref-23965506','lexi-content-ref-31371035','lexi-content-ref-31165430','lexi-content-ref-18029426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27722026','lexi-content-ref-26855096','lexi-content-ref-32075794','lexi-content-ref-27637098','lexi-content-ref-9040933','lexi-content-ref-28383363','lexi-content-ref-18188866','lexi-content-ref-12013367','lexi-content-ref-31635997','lexi-content-ref-18460039','lexi-content-ref-23965506','lexi-content-ref-31371035','lexi-content-ref-31165430','lexi-content-ref-18029426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via inhibition of serotonin-mediated platelet activation (inhibition of the serotonin reuptake transporter) and subsequent platelet dysfunction. Venlafaxine is considered to display moderate affinity for the serotonin reuptake receptor. SNRIs may also increase gastric acidity, which can increase the risk of gastrointestinal bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-18188866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-18188866'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; based on data evaluating SSRIs, it has been suggested that the onset of risk is likely delayed for several weeks until SNRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>), although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of antiplatelets and/or anticoagulants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-18606952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-18606952'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-18606952','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-18606952','lexi-content-ref-17506225'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Blood pressure elevations</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-dependent blood pressure increases have been reported; most occurrences are modest elevations and not clinically significant. Clinically significant <b>increased blood pressure</b> or <b>hypertension </b>have been observed, predominately in patients receiving high daily doses. <b>Sinus tachycardia </b>has also been reported (rarely) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16989912','lexi-content-ref-18445706','lexi-content-ref-8530334','lexi-content-ref-26096556','lexi-content-ref-31688406','lexi-content-ref-21407890','lexi-content-ref-9818630','lexi-content-ref-9565731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16989912','lexi-content-ref-18445706','lexi-content-ref-8530334','lexi-content-ref-26096556','lexi-content-ref-31688406','lexi-content-ref-21407890','lexi-content-ref-9818630','lexi-content-ref-9565731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; believed to increase blood pressure via its noradrenergic mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096556','lexi-content-ref-9818630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096556','lexi-content-ref-9818630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hypertension (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9818630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9818630'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9818630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9818630'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9818630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9818630'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years of age) suggest venlafaxine may be associated with an increased risk of bone fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21810375','lexi-content-ref-24566587','lexi-content-ref-26032210','lexi-content-ref-22659406','lexi-content-ref-23358607','lexi-content-ref-30964616','lexi-content-ref-26126579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21810375','lexi-content-ref-24566587','lexi-content-ref-26032210','lexi-content-ref-22659406','lexi-content-ref-23358607','lexi-content-ref-30964616','lexi-content-ref-26126579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by serotonergic agents (selective serotonin reuptake inhibitors [SSRIs] or serotonin norepinephrine reuptake inhibitors [SNRIs]) on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity. Of note, data evaluating the effects of serotonergic agents on bone mineral density primarily involve SSRIs rather than SNRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24566587','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24566587','lexi-content-ref-30775508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long-term use (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal hepatic function tests</b> may occur with use; <b>increased serum alanine aminotransferase </b> is usually modest and self-limiting. However, postmarketing cases of <b>hepatotoxicity</b>, including <b>hepatitis</b>, <b>cholestatic hepatitis</b>, and <b>hepatic failure</b>, have been reported rarely, including cases occurring in patients without risk factors. The pattern of hepatic injury associated with venlafaxine has varied from cholestatic to <b>hepatocellular hepatitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842767','lexi-content-ref-10691596','lexi-content-ref-27508501','lexi-content-ref-20975814','lexi-content-ref-19857765','lexi-content-ref-10375350','lexi-content-ref-23914755','lexi-content-ref-14742779','lexi-content-ref-24362450','lexi-content-ref-19841512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842767','lexi-content-ref-10691596','lexi-content-ref-27508501','lexi-content-ref-20975814','lexi-content-ref-19857765','lexi-content-ref-10375350','lexi-content-ref-23914755','lexi-content-ref-14742779','lexi-content-ref-24362450','lexi-content-ref-19841512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown by which venlafaxine may cause liver injury; however, since metabolism occurs in the liver, primarily by CYP2D6, hepatotoxicity may be mediated by toxic intermediates of that metabolism. In addition, venlafaxine is susceptible to drug-drug interactions with agents that alter these microsomal enzymes. Idiosyncratic drug-induced liver injury (DILI) is due to either direct cellular injury (metabolic idiosyncratic DILI) or are immune mediated (immune-allergic idiosyncratic DILI). Both metabolic and immunoallergic mechanisms have been suggested for venlafaxine; however, it has been reported that autoimmune (autoantibodies) and immunoallergic features (rash, fever, eosinophilia), more indicative of an immune-allergic mechanism, have been uncommon features or mild in cases of venlafaxine-associated DILI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27842767','lexi-content-ref-27508501','lexi-content-ref-23914755','lexi-content-ref-24362450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27842767','lexi-content-ref-27508501','lexi-content-ref-23914755','lexi-content-ref-24362450'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; DILI associated with antidepressant use usually occurs within several days to 6 months after initiation. In a case series of DILI associated with venlafaxine, the induction period ranged from 4 weeks to 10 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-23914755','lexi-content-ref-24362450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-23914755','lexi-content-ref-24362450'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Polypharmacy, particularly with concomitant administration of multiple agents metabolized by the same CYP450 isoenzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-24362450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-24362450'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine is associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>)<b></b>and/or <b>hyponatremia </b>(including severe cases), predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-27773479','lexi-content-ref-23686044','lexi-content-ref-9169969','lexi-content-ref-27194321','lexi-content-ref-9475820','lexi-content-ref-9232089','lexi-content-ref-17189754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-27773479','lexi-content-ref-23686044','lexi-content-ref-9169969','lexi-content-ref-27194321','lexi-content-ref-9475820','lexi-content-ref-9232089','lexi-content-ref-17189754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) via serotonin effects on 5-HT receptors and norepinephrine effects on alpha-1 adrenergic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26975593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26975593'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; based on data involving selective serotonin reuptake inhibitors (SSRIs), hyponatremia usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on data involving SSRIs, risk factors include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of hyponatremia (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Symptoms of psychosis (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin norepinephrine reuptake inhibitors (SNRIs) are associated with <b>acute angle-closure glaucoma</b> (AACG) in case reports. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15746956','lexi-content-ref-27993931','lexi-content-ref-30278181','lexi-content-ref-29893371']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15746956','lexi-content-ref-27993931','lexi-content-ref-30278181','lexi-content-ref-29893371'])">Ref</a></span>). In addition, SNRIs may be associated with an increased risk of cataract development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28342338','lexi-content-ref-24631758','lexi-content-ref-20207418','lexi-content-ref-25943730','lexi-content-ref-11999245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28342338','lexi-content-ref-24631758','lexi-content-ref-20207418','lexi-content-ref-25943730','lexi-content-ref-11999245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> AACG: Unclear; hypothesized SNRIs may increase the intraocular pressure via serotonergic and adrenergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28257449','lexi-content-ref-27993931','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28257449','lexi-content-ref-27993931','lexi-content-ref-30278181'])">Ref</a></span>). In addition, a pseudo-anticholinergic (although debatable for SNRIs) and a dopaminergic effect on ocular tissue cannot be excluded as potential mechanisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30278181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients of Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851','lexi-content-ref-30278181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851','lexi-content-ref-30278181'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at high therapeutic doses or supratherapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16882112','lexi-content-ref-9562139','lexi-content-ref-9785164','lexi-content-ref-22752315','lexi-content-ref-27644102','lexi-content-ref-11816261','lexi-content-ref-12549949','lexi-content-ref-24153222','lexi-content-ref-20814334','lexi-content-ref-30008467','lexi-content-ref-24022904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16882112','lexi-content-ref-9562139','lexi-content-ref-9785164','lexi-content-ref-22752315','lexi-content-ref-27644102','lexi-content-ref-11816261','lexi-content-ref-12549949','lexi-content-ref-24153222','lexi-content-ref-20814334','lexi-content-ref-30008467','lexi-content-ref-24022904'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors (5-HT<sub>2A</sub>) by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; onset is typically within hours of an exposure (but delays of 24 hours or longer have been reported) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism (eg, monoamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine is commonly associated with <b>sexual disorder</b> in both men and women. The following adverse reactions have been associated with use: <b>Abnormal orgasm</b>, <b>anorgasmia</b>, <b>erectile dysfunction</b>, <b>decreased libido</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21701626','lexi-content-ref-10830148','lexi-content-ref-21772780','lexi-content-ref-11229449','lexi-content-ref-18211302','lexi-content-ref-19440080','lexi-content-ref-17087787']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21701626','lexi-content-ref-10830148','lexi-content-ref-21772780','lexi-content-ref-11229449','lexi-content-ref-18211302','lexi-content-ref-19440080','lexi-content-ref-17087787'])">Ref</a></span>). <b>Priapism </b>has also been reported with duloxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24758982','lexi-content-ref-10638063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24758982','lexi-content-ref-10638063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Based on data involving selective serotonin reuptake inhibitors, it has been postulated that increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone’s effect on sexual arousal and dopamine’s role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age, a decreased risk was observed, per the manufacturer’s labeling. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-15883980','lexi-content-ref-26819231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25693810','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231','lexi-content-ref-15883980','lexi-content-ref-26819231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is that antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms, leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to longer-term use (ie, &gt;4 months). In a large cohort study of adults 20 to 64 years of age, the rates of attempted suicide or self-harm in venlafaxine users were highest in the first 28 days of initiating treatment and in the first 28 days after stopping treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25693810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25693810'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological/behavioral symptoms (eg, aggressive behavior, anxiety, agitation, confusion, insomnia, irritability, mania, violent behavior), have been reported with serotonin norepinephrine reuptake inhibitors, primarily following abrupt discontinuation. Symptoms may be severe. Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30016772','lexi-content-ref-28554948','lexi-content-ref-30817861','lexi-content-ref-28976215','lexi-content-ref-19337457','lexi-content-ref-21448114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30016772','lexi-content-ref-28554948','lexi-content-ref-30817861','lexi-content-ref-28976215','lexi-content-ref-19337457','lexi-content-ref-21448114'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the serotonergic agent. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in case reports of withdrawal symptoms following venlafaxine discontinuation, symptoms usually appeared within a period of 24 to 48 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9762390','lexi-content-ref-30016772']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9762390','lexi-content-ref-30016772'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted for &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F233726"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Actual frequency may be dependent upon formulation and/or indication. Adverse reactions are reported for the ER tablet and ER capsule formulations. Reported adverse reactions are for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (not necessarily associated with anorexia: children and adolescents: 18% to 47%; adults: &lt;7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (8% to 22%), nausea (30%), xerostomia (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (13%), dizziness (16%), drowsiness (15%), insomnia (17% to 24%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasodilation (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (5%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span>, hypercholesterolemia (5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Venlafaxine: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,558</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,197</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (9%), diarrhea (8%), vomiting (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal orgasm (males: ≤10%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Orgasm table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-orgasm" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-orgasm')">table 2</a>)</span><span class="table-link" style="display:none;">Abnormal Orgasm</span>, anorgasmia (2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Anorgasmia table link" class="lexi-table-link" data-table-id="lexi-content-anorgasmia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anorgasmia')">table 3</a>)</span><span class="table-link" style="display:none;">Anorgasmia</span>, ejaculatory disorder (≤10%), erectile dysfunction (5%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Orgasm" frame="border" id="lexi-content-abnormal-orgasm" rules="all">
<caption style="text-align:center;">
<b>Venlafaxine: Adverse Reaction: Abnormal Orgasm</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,440</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">923</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Described as "abnormal ejaculation/orgasm"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anorgasmia" frame="border" id="lexi-content-anorgasmia" rules="all">
<caption style="text-align:center;">
<b>Venlafaxine: Adverse Reaction: Anorgasmia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Venlafaxine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,440</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">923</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release capsules</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,118</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,274</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (3%), nervousness (7% to 10%), paresthesia (2%), tremor (5%), yawning (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Hypomania, manic reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Ecchymoses, pruritus, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, increased serum triglycerides, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents), dysgeusia, dyspepsia (children and adolescents), gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, chills, confusion, depersonalization, hallucination, headache, hypertonia, seizure, suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Linear skeletal growth rate below expectation (children and adolescents, most notable for age &lt;12 years), myalgia (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (takotsubo) (Vasudev 2016), heart failure (including worsening of heart failure) (Colucci 2008, Uvais 2022), hypertension (Pardal 2001), hypertensive crisis (Khurana 2003), orthostatic hypotension (Duggal 2001), prolonged QT interval on ECG (Aronow 2020), sinus tachycardia (Osuagwu 2019), torsades de pointes (Aronow 2020), ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (O’Bryan 2004), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth (Kameg 2022), hyperprolactinemia (Kameg 2022), hypoglycemia (Ozdemir 2022), hyponatremia (literature suggests an incidence ranging from &lt;1% to 39% and even as high as 70%) (De Picker 2014; Jung 2011, Kirby 2002), lactic acidosis (Ozdemir 2022), SIADH (Romero 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bruxism (Jose 2015), gingival hemorrhage (Yavasoglu 2008), mucous membrane bleeding, pancreatitis (Sevastru 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Postpartum hemorrhage (Perrotta 2019), priapism (Samuel 2000), sexual disorder (Kennedy 2000), urinary incontinence (Selvaraji 2015), urinary retention (Tuman 2021), vaginal hemorrhage (Linnebur 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, bruise (Carpenter 2016), neutropenia, pancytopenia, prolonged bleeding time, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (including increased serum alanine aminotransferase and increased serum aspartate aminotransferase) (Park 2013), cholestatic hepatitis (Stadlmann 2012), hepatic failure (Voican 2014), hepatitis (Horsmans 1999), hepatocellular hepatitis (Park 2013), hepatotoxicity (Yildirim 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Griffin 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (Ceylan 2016), anosmia (including hyposmia), apathy (Sato 2020), ataxia, balance impairment, delirium, extrapyramidal reaction, hyperactive behavior (children and adolescents treated for ADHD) (Olvera 1996), kleptomania (Sakurada 2021), myoclonus (Dutra 2008), neuroleptic malignant syndrome, serotonin syndrome (Pan 2003), withdrawal syndrome (literature suggests an incidence ranging from 23% to 78%; can be severe, may include aggressive behavior, violent behavior, or blurred vision) (Fava 2018; Sabljić 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, dystonia, rhabdomyolysis, tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (Ng 2002; Zhou 2018), increased intraocular pressure (open-angle glaucoma) (Botha 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, eosinophilic pneumonitis (Fleisch 2000), interstitial lung disease (Oh 2014), respiratory failure (Fleisch 2000)</p></div>
<div class="block coi drugH1Div" id="F233742"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to venlafaxine or any component of the formulation; use of monoamine oxidase inhibitors (MAOIs) (concurrently or within 14 days of discontinuing the MAOI); initiation of MAOI within 7 days of discontinuing venlafaxine; initiation in patients receiving IV methylene blue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although venlafaxine is contraindicated per the manufacturer labeling when used in combination with linezolid, new evidence suggests that the combination is unlikely to cause serotonin syndrome (0.06% to 3% risk), and therefore these agents can be administered concomitantly when necessary. Monitor patients on this combination; average duration of serotonin toxicity is ~4 days; however, risks may be greater with longer durations of concurrent therapy. Educate patients on the signs and symptoms of serotonin syndrome (Bai 2022; Butterfield 2012; Karkow 2017; Kufel 2023; Narita 2007; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F233723"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use caution in patients with recent history of MI, unstable heart disease, cerebrovascular conditions, or hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use caution in patients with a previous seizure disorder; discontinue in any patient who develops seizures.</p></div>
<div class="block foc drugH1Div" id="F233734"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effexor XR: 37.5 mg, 75 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37.5 mg, 75 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as besylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 112.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37.5 mg, 75 mg, 150 mg, 225 mg</p></div>
<div class="block geq drugH1Div" id="F233719"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F233744"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Effexor XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $19.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $21.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $23.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Venlafaxine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $0.48 - $6.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $0.53 - $6.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.59 - $7.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Venlafaxine Besylate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">112.5 mg (per each): $7.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Venlafaxine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $2.26 - $8.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $1.49 - $9.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.62 - $10.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">225 mg (per each): $1.54 - $20.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Venlafaxine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $2.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.31 - $2.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868588"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Effexor XR: 37.5 mg, 75 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37.5 mg, 75 mg, 150 mg</p></div>
<div class="block adm drugH1Div" id="F233739"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">ER formulations: Administer either in the morning or in the evening at approximately the same time each day. Swallow capsule or tablet whole with fluid; do not divide, crush, chew, or place in water. Contents of capsule may be sprinkled on a spoonful of applesauce and swallowed immediately without chewing; followed with a glass of water to ensure complete swallowing of the pellets.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet and ER capsule formulations that can be opened and sprinkled over soft food are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block admp drugH1Div" id="F52614004"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release tablet: Administer with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended-release capsule (hydrochloride salt; eg, Effexor XR): Administer with food once daily at about the same time each day; swallow whole with fluid; do not crush, chew, divide, or place in water; capsule may be opened and entire contents sprinkled on spoonful of applesauce; swallow drug/food mixture immediately. Do not store for future use; do not chew contents (ie, pellets) of capsule; follow drug/food mixture with water to ensure complete swallowing of pellets.</p></div>
<div class="block meg drugH1Div" id="F7874929"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Effexor XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020699s118lbl.pdf%23page%3D41&amp;token=mUNUMz6OpeM2hEiL6d3%2BJhTfrwrVPCZjG9KJkgYiLHgdF608pofddFbTWmFLYWYyA2l5lNVSaReGIrM74NrCvR7XwmdVqaXONX7RaZMZZgURkqQw3avYKslPPiyAF7md&amp;TOPIC_ID=10042" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf#page=41</a></p>
<p style="text-indent:-2em;margin-left:4em;">Venlafaxine ER tablet: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022104s023lbl.pdf%23page%3D35&amp;token=JVijp5QmAyqGU3ey9KXKBxkNYJPzRb6XS1JsU%2F4lcDPTDttsP%2BZPUDTOIFERzbSK2C5uVCdkiQLU3%2BDjvRLK4CwsRtAPao%2B%2FTUccBVpYiCalYwcfMPPx4Ofeb2UpfJUq&amp;TOPIC_ID=10042" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022104s023lbl.pdf#page=35</a></p>
<p style="text-indent:-2em;margin-left:4em;">Venlafaxine besylate ER tablet: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215429s001lbl.pdf%23page%3D33&amp;token=N620pIxKMs1pznuTjoTwqb0I6YEFXHakzxRryUCas2Iz9qGmqEsbPtEZWSeO6IvEmQgvEQ3RFqTp8qd19qqNitdHthapVURVQAudBsVNyUkHK31Jk4DmPhf9aydmuIGz&amp;TOPIC_ID=10042" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215429s001lbl.pdf#page=33</a></p></div>
<div class="block use drugH1Div" id="F233738"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (ER hydrochloride capsules and ER besylate tablets only):</b> Treatment of generalized anxiety disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Treatment of unipolar major depressive disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder (ER hydrochloride capsules only):</b> Treatment of panic disorder, with or without agoraphobia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (ER hydrochloride capsules and tablets only):</b> Treatment of social anxiety disorder, also known as social phobia.</p></div>
<div class="block off-label drugH1Div" id="F25744938"><span class="drugH1">Use: Off-Label: Adult</span><p>Migraine, prevention; Narcolepsy with cataplexy; Neuropathic pain associated with diabetes mellitus; Obsessive-compulsive disorder; Posttraumatic stress disorder; Premenstrual dysphoric disorder; Vasomotor symptoms associated with menopause</p></div>
<div class="block mst drugH1Div" id="F7914389"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Effexor may be confused with Effexor XR</p>
<p style="text-indent:-2em;margin-left:4em;">Effexor XR may be confused with Enablex</p>
<p style="text-indent:-2em;margin-left:4em;">Venlafaxine may be confused with Venclexta, venetoclax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) (venlafaxine) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F233795"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F233728"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Consider advising patients to avoid concomitant use of alcohol with SNRIs, particularly those using extended-release SNRI formulations, due to the risk of accelerated drug release. Heavy alcohol use has been associated with overdose and hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.  Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Alpha2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Venlafaxine may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May increase the serum concentration of Venlafaxine. Venlafaxine may increase the serum concentration of Propafenone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Venlafaxine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Venlafaxine. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): Venlafaxine may enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). Venlafaxine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may decrease serum concentrations of the active metabolite(s) of Venlafaxine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Venlafaxine.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of other Serotonin/Norepinephrine Reuptake Inhibitors. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of other Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the adverse/toxic effect of TraMADol. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54047277"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Venlafaxine is approved for the treatment of major depressive disorder. If treatment for major depressive disorder is initiated for the first time in patients planning to become pregnant, agents other than venlafaxine are preferred (Larsen 2015).</p>
<p style="text-indent:0em;">Venlafaxine is effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p></div>
<div class="block pri drugH1Div" id="F233745"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Venlafaxine and its active metabolite O-desmethylvenlafaxine (ODV) cross the human placenta (Rampono 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Nonteratogenic adverse events have been observed with venlafaxine or other SNRIs/SSRIs when used during pregnancy. Cyanosis, apnea, respiratory distress, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyperreflexia, jitteriness, irritability, constant crying, and tremor have been reported in the neonate immediately following delivery after exposure to venlafaxine, SSRIs, or other SNRIs late in the third trimester. Prolonged hospitalization, respiratory support, or tube feedings may be required. Some symptoms may be due to the toxicity of the SNRI/SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of venlafaxine may be altered. Pregnant patients should be monitored for decreased efficacy (Klier 2007; ter Horst 2014; Westin 2018). The risk of bleeding, including postpartum hemorrhage, may be increased following maternal use of venlafaxine (Palmsten 2013; Reis 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006). If treatment for major depressive disorder is initiated for the first time during pregnancy, agents other than venlafaxine are preferred (CANMAT [MacQueen 2016]; Larsen 2015). Patients effectively treated with venlafaxine prior to pregnancy may continue treatment (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). Efficacy of venlafaxine for migraine prevention in pregnancy is limited and use is not recommended (ACOG 2022; CHS [Pringsheim 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Patients 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>
<div class="block brc drugH1Div" id="F233746"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine and the active metabolite O-desmethylvenlafaxine (ODV) are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of venlafaxine in breast milk are available from multiple sources (Berle 2004; Ilett 1998; Ilett 2002; Misri 2006; Newport 2009; Schoretsanitis 2019; Weissman 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">• In 1 study, the transfer of venlafaxine and ODV into breast milk was evaluated in 13 mother-infant pairs. All patients in the study had been taking venlafaxine for &gt;2 weeks (mean dose: 194 mg/day; range: 37.5 to 300 mg/day). All but 2 were using the extended-release dosage form. Milk samples were obtained over 24 hours. Mean breast milk concentrations were 469.8 ng/mL (venlafaxine) and 919 ng/mL (ODV). The maximum venlafaxine milk concentration reported was 2,759 ng/mL (maternal dose 187.5 mg/day) and the maximum ODV milk concentration reported was 3,146 ng/mL (maternal venlafaxine dose 225 mg/day). The mean theoretical infant dose (venlafaxine + ODV) was 0.21 mg/kg/day (range: 0.071 to 0.375 mg/kg/day). The mean relative infant dose (RID) was calculated to be 8.1% of the maternal dose (range: 5% to 13%). The amount of ODV in breast milk increased over time and was greater 12 hours after the dose than earlier in the sampling interval. In 6 mother-infant pairs, maternal and infant serum samples were taken. In the breastfeeding infants, mean plasma concentrations were 2.5 ng/mL (venlafaxine) and 58.7 ng/mL (ODV) and mean maternal plasma concentrations were 71.6 ng/mL (venlafaxine) and 245.6 ng/mL (ODV). Adverse effects were not reported in the 13 breastfeeding infants, all generally healthy at delivery (mean age: 20.9 weeks, range: 6.4 to 60 weeks) (Newport 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Infants of mothers using psychotropic medications should be monitored daily for changes in sleep, feeding patterns, and behavior (WFSBP [Bauer 2013]) as well as infant growth and neurodevelopment (ABM [Sriraman 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; antidepressant medication is recommended when psychotherapy is not an option or symptoms are moderate to severe. When first initiating an antidepressant in a breastfeeding patient, agents other than venlafaxine are preferred (ABM [Sriraman 2015]; CANMAT [MacQueen 2016]; Larsen 2015). A patient already stabilized on a serotonin/norepinephrine reuptake inhibitor during pregnancy may continue that medication while breastfeeding (ABM [Sriraman 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, preventive treatment for migraine in breastfeeding patients should be avoided. When needed, therapy should be individualized considering the available safety data and needs of the patient (AHS [Ailani 2021]). Agents other than venlafaxine are recommended when preventive therapy is needed in patients who are lactating (CHS [Pringsheim 2012]).</p></div>
<div class="block mop drugH1Div" id="F233731"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP should be regularly monitored, especially in patients with a high baseline BP pressure; may cause mean increase in heart rate of 4 to 9 beats/minute; lipid panel; screen patients for personal or family history of bipolar disorder, mania, or hypomania prior to initiating therapy; closely monitor patients for depression, clinical worsening, suicidality, psychosis, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, social functioning), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); hyponatremia, discontinuation symptoms; height and weight should be monitored in children; intraocular pressure and mydriasis (in patients with raised ocular pressure or at risk of acute narrow angle glaucoma) (APA 2010).</p></div>
<div class="block pha drugH1Div" id="F233722"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant activity for muscarinic cholinergic, H<sub>1</sub>-histaminergic, or alpha<sub>2</sub>-adrenergic receptors. Venlafaxine and ODV do not possess MAO-inhibitory activity. Venlafaxine functions like an SSRI in low doses (37.5 mg/day) and as a dual mechanism agent affecting serotonin and norepinephrine at doses above 225 mg/day (Harvey 2000; Kelsey 1996).</p></div>
<div class="block phk drugH1Div" id="F233741"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (generalized anxiety, panic, obsessive-compulsive disorder [OCD], posttraumatic stress disorder [PTSD]): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with OCD and PTSD (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: ≥92%; extended release has a slightly slower rate of absorption compared to immediate-release.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Venlafaxine 7.5 ± 3.7 L/kg, ODV 5.7 ± 1.8 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Venlafaxine 27% ± 2%, ODV 30% ± 12%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP2D6 to active metabolite, O-desmethylvenlafaxine (ODV); other metabolites include N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Venlafaxine: 5 ± 2 hours (immediate-release), 6.8 ± 1.6 hours (ER besylate), 10.7 ± 3.2 hours (ER hydrochloride); ODV: 11 ± 2 hours (immediate-release), 11.3 ± 2.3 hours (ER besylate), 12.5 ± 3 hours (ER hydrochloride); prolonged with cirrhosis (venlafaxine: ~30%, ODV: ~60%), renal impairment (venlafaxine: ~50%, ODV: ~40%), and during dialysis (venlafaxine: ~180%, ODV: ~142%)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Venlafaxine: 2 hours, ODV: 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">ER besylate: Venlafaxine: 10 hours (range: 5 to 18 hours), ODV: 18 hours (range: 5 to 28 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">ER hydrochloride: Venlafaxine: 6.3 ± 2.3 hours, ODV: 11.6 ± 2.9 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~87%; 5% of total dose as unchanged drug; 29% of total dose as unconjugated ODV; 26% of total dose as conjugated ODV; 27% of total dose as minor inactive metabolites).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with cirrhosis: Venlafaxine: Clearance is decreased by ~50%; ODV: Clearance is decreased by ~30%.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with more severe cirrhosis: Venlafaxine: Clearance is decreased by ~90%.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with renal impairment (GFR: 10 to 70 mL/minute): Venlafaxine: Clearance is decreased by ~24%; ODV: Clearance unchanged versus normal subjects.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults on dialysis: Venlafaxine: Clearance decreased by ~57%; ODV: Clearance decreased by ~56%.</p></div>
<div class="block phksp drugH1Div" id="F51204425"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life is prolonged and clearance is reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Elimination half-life is prolonged and clearance decreased. In patients with Child-Pugh class A and Child-Pugh class B hepatic impairment, venlafaxine oral bioavailability was increased 2- to 3-fold, and clearance was reduced by 40% (Mullish 2014; manufacturer’s labeling). In patients with Child-Pugh class C hepatic impairment, clearance was reduced by 90% (Mullish 2014).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233748"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Velexel | Venex xr | Venlax | Venlift xr</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alfaxin | Efexor | Elafax | Faxipaw | Ganavax | Maxibral xr | Pramina | Psiseven | Quilarex | Quilarex XR | Sesaren | Sunvex LP | Venlafaxina cevallos | Venlafaxina dosa | Venlifax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Efectin | Velostad | Venaxibene | Venlafab | Venlafaxin +pharma | Venlafaxin 1A Pharma | Venlafaxin Actavis | Venlafaxin Arcana | Venlafaxin bluefish | Venlafaxin Easypharm | Venlafaxin G.L. | Venlafaxin Genericon | Venlafaxin Hexal | Venlafaxin krka | Venlafaxin pfizer | Venlafaxin Ranbaxy | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxin Stada | Venlafaxin viatris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alembic venlafaxine xr | Altven | Apo venlafaxine xr | Blooms the chemist venlafaxine | Chemmart venlafaxine | Efexor | Efexor xr | Elaxine sr | Enlafax xr | Sandoz venlafaxine xr | Stada venlafaxine | Terry white chemists venlafaxine | Venla rbx | Venlabic xr | Venlafaxine actavis | Venlafaxine agh xr | Venlafaxine aghl xr | Venlafaxine agl xr | Venlafaxine agpl xr | Venlafaxine alem xr | Venlafaxine alembic xr | Venlafaxine alma xr | Venlafaxine alsa xr | Venlafaxine an | Venlafaxine apal xr | Venlafaxine apel xr | Venlafaxine apgh xr | Venlafaxine apl xr | Venlafaxine appl xr | Venlafaxine generichealth xr | Venlafaxine medis xr | Venlafaxine Sandoz | Venlafaxine scp | Venlexor</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Veniz | Venlaf | Venlax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor exel | Venlabloxus | Venlafaxin sandoz | Venlafaxine | Venlafaxine EG | Venlafaxine Mylan | Venlafaxine ranbaxy | Venlafaxine Sandoz | Venlafaxine Teva | Venlasand | Vennaxa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Deprexor | Efectin | Efectin er | Efexiva | Elify | Lanvexin | Laroxin | Tifaxin mr | Velaxin | Venlacon | Venlafectin | Venlagamma</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alenthus | Cloridato de venlafaxina | Cloridrato de Venlafaxin | Cloridrato de venlafaxina | Efexor | Efexor xr | Myletin | Novidat | Venforin | Veniz | Venlafaxina | Venlaxin | Venlift | Vensate lp</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor er | Venlafaxin Actavis | Venlafaxin eco | Venlafaxin helvepharm | Venlafaxin Mepha | Venlafaxin pfizer | Venlafaxin ret Zentiva | Venlafaxin sandoz | Venlafaxin spirig | Venlafaxin Teva | Venlax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Effexor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Axone xr | Depurol | Ectien xr | Efexor xr | Lafaxin | Nervix | Nezel xr | Norpilen | Senexon | Sentidol | Sesaren | Subelan XR | Vencontrol | Venlakem | Venlavitae xr | Venlax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo le xin | Efexor xr</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Desmaril | Eduxon | Efexor | Efexor xr | Niztec | Norpilen | Vendep | Venlafaxina | Venlax | Venoxor | Vilfax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Venlafaxin | Argofan | Convalemin | Depant | Efectin | Faxiprol | Mollome | Nopekar | Olwexya | Tifaxin | Venlafaxin Mylan | Venlafaxin orion | Venlafaxin Pliva | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxin Teva | Venlafaxine Bluefish | Venlagamma</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Trevilor | Vandral | Venla | Venla Q | Venla teva | Venlafaxin | Venlafaxin 1A Pharma | Venlafaxin Aaa | Venlafaxin AbZ | Venlafaxin Acis | Venlafaxin Actavis | Venlafaxin AL | Venlafaxin aristo | Venlafaxin Atid | Venlafaxin aurobindo | Venlafaxin AWD | Venlafaxin Axcount | Venlafaxin Basics | Venlafaxin Beta | Venlafaxin Billix | Venlafaxin Biomo | Venlafaxin bluefish | Venlafaxin CT | Venlafaxin dexcel | Venlafaxin Dura | Venlafaxin Fair Med | Venlafaxin farmaprojects | Venlafaxin Hennig | Venlafaxin Heumann | Venlafaxin Hexal | Venlafaxin Hormosan | Venlafaxin Krewel | Venlafaxin neuraxpharm | Venlafaxin puren | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxin Stada | Venlafaxin Sun | Venlafaxin TAD | Venlafaxin Teva | Venlafaxin Valeant | Venlafaxin Winthrop | Venlafaxin Winthrop osmo | Venlafaxine axunio | Venlagamma | Venlasan</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Duofaxin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Efexor xr | Effexor | Elafax | Lafaxin | Venfane | Venlafran | Veslodat</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ansifix | Efexor xr | Oxialpress | Sesaren xr | Veniz | Venlafaxina mk</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Argofan | Efexor | Venlafaxin Medochemie | Venlafaxin Portfarma | Venlafaxin Ratiopharm | Venlafaxine Elvim | Venlafaxine Orion | Venlafaxine Portfarma | Venlagamma</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Effegad | Effoxbelle | Idixor | Venlafax | Venlatrin | Venlaxine | Venoxor | Vexamod</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arafaxina | Conervin | Dislaven | Dobupal | Flaxen | Levest | Vandral | Venlabrain | Venlafaxin Actavis | Venlafaxin Alter | Venlafaxin curaxys | Venlafaxina Apotex | Venlafaxina Asol | Venlafaxina aurobindo | Venlafaxina Bexal | Venlafaxina Bluefish | Venlafaxina Cinfa | Venlafaxina Combix | Venlafaxina Davur | Venlafaxina Kern pharma | Venlafaxina krka | Venlafaxina Mabo | Venlafaxina mylan | Venlafaxina Normon | Venlafaxina Onedose | Venlafaxina Pharmagenus | Venlafaxina Qualigen | Venlafaxina Ranbaxy | Venlafaxina ratiopharm | Venlafaxina Retard Salutas | Venlafaxina retard stada | Venlafaxina Rimafar | Venlafaxina sandoz | Venlafaxina Stada | Venlafaxina Sumol | Venlafaxina sun | Venlafaxina Tecnigen | Venlafaxina Teva | Venlafaxina Vegal | Venlafaxina Winthrop | Venlafaxine retard alter generic | Venlamylan | Venlapine | Zarelis | Zarelis retard</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Venlafaxine aurobindo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor depot | Venlafaxin Actavis | Venlafaxin Hexal | Venlafaxin krka | Venlafaxin Mylan | Venlafaxin Orifarm | Venlafaxin orion | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxin Stada | Venlafaxine Bluefish | Venlafaxine Teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Effexor | Venlafaxine abbott | Venlafaxine actavis | Venlafaxine Almus | Venlafaxine Alter | Venlafaxine Arrow | Venlafaxine Biogaran | Venlafaxine Bluefish | Venlafaxine bouchara | Venlafaxine Cristers | Venlafaxine dakota | Venlafaxine EG | Venlafaxine Evolupharm | Venlafaxine Isomed | Venlafaxine Krka | Venlafaxine Mylan | Venlafaxine Qualimed | Venlafaxine ranbaxy | Venlafaxine ranbaxy LP | Venlafaxine ratiopharm | Venlafaxine Sandoz | Venlafaxine teva sante lp | Venlafaxine Wyeth | Venlafaxine Zydus | Venlafaxine Zydus france</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amphero | Apclaven | Axyven | Depefex xl | Efexor | Hapixed | Majoven xl | Politid xl | Sivion XL | Sunveniz | Tonpular XL | Venlablue | Venladex | Venlafaxine | Venlalic | Venlaneo | Venzip xl | Viepax | Viepax xl | Xenalven xl</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Arvifax | Deprevix | Efexor | Melocin | Memomax-S | Norafexine | Norezor | Serosmine | Velpine | Ven fax | Venaxol | Venlafaxine generics | Venlafaxine Teva | Venlafaxine/mylan | Venlasan | Venlaxin | Voxafen | Zacalen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Deprevix | Efexor | Venlafaxine Sandoz | Venlor | Venxor</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Faxiven | Velafax | Velafax XL</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arixen | Efectin | Falven | Faxiprol | Fobiven | Jarvis | Nopekar | Velaxin | Venlafaxin | Venlafaxin bluefish | Venlafaxin orion | Venlafaxin Zentiva | Venlagamma | Venlaxgen | Ventadepress</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Efexor xr</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Efaxil | Efexor | Ireven | Sivion XL | Sunveniz | Tonpular XL | Vedixal | Venex | Venlablue | Venlafaxine Teva | Venlafex | Venlafex xl | Venlift | Venlofex | Vensir</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Venla | Viepax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dalium | Envelaf xr | Flavix | Livenfax | Sentosa | Velaf | Velax | Ven-od | Venaxin | Venfax-pr | Veniz | Venjoy | Venla | Venlife er | Venlift | Venlor | Ventab | Ventee | Ventin | Ventodep | Venx | Venzup-xr | Vexor | Vinfax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Faxine | Ixilania | Tifaxin | Venlafaxina | Venlafaxina Alt | Venlafaxina aurobindo | Venlafaxina Bluefish | Venlafaxina Doc | Venlafaxina EG | Venlafaxina fdi | Venlafaxina Germed | Venlafaxina mylan | Venlafaxina pns | Venlafaxina Ranbaxy | Venlafaxina sandoz | Venlafaxina Winthrop | Zarelis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Vaxor | Venexor | Venzor XR</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Effexor | Vencir | Veniz | Venlift | Ventab xl</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cofexor | Depron | Efexor | Efexor xr | Ivencine sr | Lavensa | Pharma venlafaxine | Prexa | Velakan | Venexor Xr | Venfaxin | Venfaxine sr | Venlafact | Venlafaxine sr | Vivafaxine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Efexor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Defaxine | Deprevix hellas | Efexor | Venlafaxine Arrow</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Argofan | Efexor | Efexor xr | Lanvexin | Prefaxine | Venlafaxin Ratiopharm | Venlafaxin retard mylan | Venlafaxine actavis | Venlafaxine Orion | Venlafaxine Portfarma | Venlagamma | Venlaxor | Venlobax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docvenlafaxine | Efexor | Efexor exel | Venlafaxin Ratiopharm | Venlafaxine EG | Venlafaxine Sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Deprexor | Efexor | Efexor xr | Elify | Lanvexin | Prefaxine | Trevilor | Velaxin | Venlafaxin Hexal | Venlafaxin Ratiopharm | Venlafaxine actavis | Venlafaxine Orion | Venlafaxine Portfarma | Venlagamma | Venlaxor | Venlobax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Effexor | Velaxor | Vendep xr</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adefaxin XR | Belanovag | Benolaxe | Efexor | Efexor xr | Evaxiner xr | Falacap | Lafaxven | Linexel | Mazda | Odven SBK | Ralodim | Rimogrin | Tigelvet | Venlafaxina | Vextor</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Binoven er | Efexor | Efexor xr | Venxor</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Venladoz | Venlafaxine | Venlafaxine actavis | Venlafaxine Bluefish | Venlafaxine HCL | Venlafaxine Mylan | Venlafaxine PCH | Venlafaxine ratiopharm | Venlafaxine Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor depot | Venlafaxin bluefish | Venlafaxin krka | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlazid | Venlix | Venorion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow venlafaxine | Efexor | Efexor xr | Effexor | Enlafax xr</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Anapresin | Efexor xr | Norpilen xr | Noviser | Sesaren xr | Vafexin | Veniz | Ventab xl | Vfax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Venlift</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amfax | Depfit | Deprexor | Efexor | Efexor xr | Faxine | Fexor xr | Nodep | Peofax | Pracit | Velane | Velax | Venalax | Vendep | Vendep xr | Venfex | Venice | Venlazon xr | Venwell | Vinoxa | Welna xr | Wenvax | Wenvax xr | Xexor | Xifexin | Zaxine xr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Axyven | Efectin | Efevelon | Faxigen XL | Faxolet | Jarvis | Lafactin | Olwexya | Oriven | Prefaxine | Symfaxin | Velafax | Velaxin | Venlabax | Venlafaxine aurovitas | Venlafaxine Bluefish | Venlafaxine ranbaxy</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Effexor | Venlafaxine | Venlafaxine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Desinax | Efexor | Efexor xr | Genexin | Leritex | Pracet | Venlafaxina | Venlafaxina Actavis | Venlafaxina Afax | Venlafaxina anova | Venlafaxina apceuticals | Venlafaxina Azevedos | Venlafaxina Bluefish | Venlafaxina ciclum | Venlafaxina generis | Venlafaxina mylan | Venlafaxina Tolife | Venxin | Xapnev | Zarelix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Elafax | Neoxacina | Oprax sr | Sesaren xr | Venlafaxina bauel top | Venlafaxina dallas | Venlafaxina dasanti | Venlafaxina imedic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Efexor XR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adoxa ep | Alventa | Argofan | Efectin | Elify ep | Fobiless | Ivryx | Jarvis | Velaxin | Venlafaxina Actavis | Venlafaxina aurobindo | Venlafaxina lph | Venlafaxina terapia | Venlagamma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Dapfix | Efevelon | Newvelong | Velafax | Velaxin | Venlafaxine | Venlafaxine alsi | Venlafaxine organica | Venlaxor | Venlift | Vensuert | Voxemel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Pms venlafaxine XR | Velexel | Venaxine | Vexal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Efastad | Efexor | Efexor depot | Faxiprol | Vandral | Venlafaxin | Venlafaxin 1A Farma | Venlafaxin abacus medicine | Venlafaxin Actavis | Venlafaxin Agp | Venlafaxin Arrow | Venlafaxin bluefish | Venlafaxin ebb | Venlafaxin Eql Pharma | Venlafaxin Hexal | Venlafaxin krka | Venlafaxin liconsa | Venlafaxin Medical valley | Venlafaxin Mylan | Venlafaxin Orifarm | Venlafaxin orion | Venlafaxin Ranbaxy | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxin Stada | Venlatab</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Viepax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Efectin | Faxiprol | Venlafaksin Actavis | Venlagamma</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alventa | Argofan | Depant | Efectin | Faxiprol | Mollome | Nopekar | Tifaxin xr | Velafax | Velahibin | Velaxin | Venlafaxin Actavis | Venlafaxin Mylan | Venlafaxin Ratiopharm | Venlafaxin sandoz | Venlafaxine Bluefish | Venlagamma | Voxatin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Efexor xr | Valosine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Effexor | Tedema | Zenexor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Faxiven xr | Sulinex xr | Venegis XR | Veniba | Venladep</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Calmdown | Devenlofe | Easyfor sr | Efexor | Efexor xr | Faxine | Newcalm | Rafax | Valosine | Venfaxime | Venlafaxine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lafaxine xr | Medofaxin | Velaxin | Venlafaxine | Venlaxor</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Elafax | Faxine | Limbic | Nulev | Venlafaxina | Venlafaxina Szabo | Venxine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Efexor | Efexor xr | Sesaren | Vendep xr | Veniz | Venlafaxina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Efegen | Efexor | Emlev | Illovex | Illovex xr | Lafeks | Odiven | Sandoz venlafaxine xl | Vefax | Venlafaxine | Venlafaxine xr adco | Venlor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16989912">
<a name="16989912"></a>Abozguia K, Chudley S, Gammage M. Dose-dependent venlafaxine-induced sinus tachycardia. <i>Int J Cardiol</i>. 2006;113(1):E9-E10. doi:10.1016/j.ijcard.2006.01.072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16989912/pubmed" id="16989912" target="_blank">16989912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16882112">
<a name="16882112"></a>Adan-Manes J, Novalbos J, López-Rodríguez R, Ayuso-Mateos JL, Abad-Santos F. Lithium and venlafaxine interaction: a case of serotonin syndrome. <i>J Clin Pharm Ther</i>. 2006;31(4):397-400. doi:10.1111/j.1365-2710.2006.00745.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16882112/pubmed" id="16882112" target="_blank">16882112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12444814">
<a name="12444814"></a>Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. <i>J Clin Psychiatry</i>. 2002;63(11):1004-1009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12444814/pubmed" id="12444814" target="_blank">12444814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet</i>
<i>Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Published October 2010. Accessed July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32542073">
<a name="32542073"></a>Aronow WS, Shamliyan TA. Effects of antidepressants on QT interval in people with mental disorders. <i>Arch Med Sci</i>. 2020;16(4):727-741. doi:10.5114/aoms.2019.86928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/32542073/pubmed" id="32542073" target="_blank">32542073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20402746">
<a name="20402746"></a>Attal N, Cruccu G, Baron R, et al; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. <i>Eur J Neurol</i>. 2010;17(9):1113-e88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20402746/pubmed" id="20402746" target="_blank">20402746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36534400">
<a name="36534400"></a>Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. <i>JAMA Netw Open</i>. 2022;5(12):e2247426. doi:10.1001/jamanetworkopen.2022.47426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/36534400/pubmed" id="36534400" target="_blank">36534400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18837867">
<a name="18837867"></a>Benvenuti A, Rucci P, Miniati M, et al. Treatment-emergent mania/hypomania in unipolar patients. <i>Bipolar Disord</i>. 2008;10(6):726-732. doi:10.1111/j.1399-5618.2008.00613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18837867/pubmed" id="18837867" target="_blank">18837867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15367050">
<a name="15367050"></a>Berle JØ, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. <i>J Clin Psychiatry</i>. 2004;65(9):1228-1234. doi:10.4088/jcp.v65n0911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15367050/pubmed" id="15367050" target="_blank">15367050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562139">
<a name="9562139"></a>Bhatara VS, Magnus RD, Paul KL, Preskorn SH. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. <i>Ann Pharmacother</i>. 1998;32(4):432-436. doi:10.1345/aph.17041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9562139/pubmed" id="9562139" target="_blank">9562139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35963508">
<a name="35963508"></a>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. <i>Endocr Pract</i>. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/35963508/pubmed" id="35963508" target="_blank">35963508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27131226">
<a name="27131226"></a>Botha VE, Bhikoo R, Merriman M. Venlafaxine-induced intraocular pressure rise in a patient with open angle glaucoma. <i>Clin Exp Ophthalmol</i>. 2016;44(8):734-735. doi:10.1111/ceo.12769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27131226/pubmed" id="27131226" target="_blank">27131226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9762390">
<a name="9762390"></a>Boyd IW. Comment: hyponatremia with venlafaxine. <i>Ann Pharmacother</i>. 1998;32(9):981-982. doi:10.1177/106002809803200902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9762390/pubmed" id="9762390" target="_blank">9762390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome [published correction appears in <i>N Engl J Med</i>. 2007;356(23):2437] [published correction appears in <i>N Engl J Med</i>. 2009;361(17):1714]. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18314433">
<a name="18314433"></a>Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. <i>JAMA</i>. 2008;299(8):901-913. doi:10.1001/jama.299.8.901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18314433/pubmed" id="18314433" target="_blank">18314433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482920">
<a name="21482920"></a>Bril V, England J, Franklin GM, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in <i>Neurology</i>. 2011;77(6):603]. <i>Neurology</i>. 2011;76(20):1758-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21482920/pubmed" id="21482920" target="_blank">21482920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15567552">
<a name="15567552"></a>Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. <i>Clin Neurol Neurosurg</i>. 2004;107(1):44-48. doi:10.1016/j.clineuro.2004.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15567552/pubmed" id="15567552" target="_blank">15567552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27842767">
<a name="27842767"></a>Bunchorntavakul C, Reddy KR. Drug hepatotoxicity: newer agents. <i>Clin Liver Dis</i>. 2017;21(1):115-134. doi:10.1016/j.cld.2016.08.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27842767/pubmed" id="27842767" target="_blank">27842767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29099547">
<a name="29099547"></a>Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. <i>J Clin Psychiatry</i>. 2018;79(1):16m11415. doi:10.4088/JCP.16m11415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29099547/pubmed" id="29099547" target="_blank">29099547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139199">
<a name="22139199"></a>Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data.<i> J Antimicrob Chemother</i>. 2012;67(2):494-502. doi:10.1093/jac/dkr467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22139199/pubmed" id="22139199" target="_blank">22139199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10691596">
<a name="10691596"></a>Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis. <i>Ann Intern Med</i>. 2000;132(5):417. doi:10.7326/0003-4819-132-5-200003070-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10691596/pubmed" id="10691596" target="_blank">10691596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27722026">
<a name="27722026"></a>Carpenter JE, Fombi J, Udoka O, Holder-Perkins V. Venlafaxine-induced bruising: a case report. <i>Prim Care Companion CNS Disord</i>. 2016;18(3):10.4088/PCC.15l01886. doi:10.4088/PCC.15l01886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27722026/pubmed" id="27722026" target="_blank">27722026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.2020">
<a name="Casper.2020"></a>Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/treatment-of-premenstrual-syndrome-and-premenstrual-dysphoric-disorder?search=premenstrual%20dysphoric&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1#H2" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27409139">
<a name="27409139"></a>Ceylan ME, Evrensel A. Venlafaxine induced akathisia: a case report. <i>Trends Psychiatry Psychother</i>. 2016;38(2):117. doi:10.1590/2237-6089-2015-0084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27409139/pubmed" id="27409139" target="_blank">27409139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15362257">
<a name="15362257"></a>Chand PK, Kalyani GS, Murthy P. Venlafaxine-associated hypomania in unipolar depression. <i>Can J Psychiatry</i>. 2004;49(7):496. doi:10.1177/070674370404900717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15362257/pubmed" id="15362257" target="_blank">15362257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28257449">
<a name="28257449"></a>Chen VC, Ng MH, Chiu WC, et al. Effects of selective serotonin reuptake inhibitors on glaucoma: a nationwide population-based study. <i>PLoS One</i>. 2017;12(3):e0173005. doi:10.1371/journal.pone.0173005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28257449/pubmed" id="28257449" target="_blank">28257449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26579809">
<a name="26579809"></a>Cheng YL, Hu HY, Lin XH, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. <i>Medicine (Baltimore)</i>. 2015;94(46):e2022. doi:10.1097/MD.0000000000002022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26579809/pubmed" id="26579809" target="_blank">26579809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342338">
<a name="28342338"></a>Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: a population-based, nested case-control study. <i>J Affect Disord</i>. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28342338/pubmed" id="28342338" target="_blank">28342338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20975814">
<a name="20975814"></a>Christensen RC, Garces LK. Hepatotoxic effects with high-dose venlafaxine. <i>Psychiatry (Edgmont)</i>. 2006;3(7):10-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20975814/pubmed" id="20975814" target="_blank">20975814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update [published correction appears in <i>Endocr Pract</i>. 2017;23(12):1488]. <i>Endocr Pract</i>. 2017;23(7):869-880. doi:10.4158/EP171828.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15349012">
<a name="15349012"></a>Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. <i>J Clin Psychopharmacol</i>. 2004;24(5):540-543. doi:10.1097/01.jcp.0000138767.53976.10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15349012/pubmed" id="15349012" target="_blank">15349012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18445706">
<a name="18445706"></a>Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. <i>Ann Pharmacother</i>. 2008;42(6):882-887. doi:10.1345/aph.1L031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18445706/pubmed" id="18445706" target="_blank">18445706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21810375">
<a name="21810375"></a>Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. <i>Health Technol Assess</i>. 2011;15(28):1-iv. doi:10.3310/hta15280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21810375/pubmed" id="21810375" target="_blank">21810375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693810">
<a name="25693810"></a>Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. <i>BMJ</i>. 2015;350:h517. doi:10.1136/bmj.h517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25693810/pubmed" id="25693810" target="_blank">25693810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9785164">
<a name="9785164"></a>Daniels RJ. Serotonin syndrome due to venlafaxine overdose. <i>J Accid Emerg Med</i>. 1998;15(5):333-334. doi:10.1136/emj.15.5.333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9785164/pubmed" id="9785164" target="_blank">9785164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17015818">
<a name="17015818"></a>Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. <i>Arch Gen Psychiatry</i>. 2006a;63(10):1158-1165. doi:10.1001/archpsyc.63.10.1158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17015818/pubmed" id="17015818" target="_blank">17015818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16702890">
<a name="16702890"></a>Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study [published correction appears in: <i>J Clin Psychopharmacol</i>. 2006;26(5):473]. <i>J Clin Psychopharmacol</i>. 2006b;26(3):259-267. doi:10.1097/01.jcp.0000222514.71390.c1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16702890/pubmed" id="16702890" target="_blank">16702890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606952">
<a name="18606952"></a>de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. <i>Arch Gen Psychiatry</i>. 2008;65(7):795-803. doi:10.1001/archpsyc.65.7.795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18606952/pubmed" id="18606952" target="_blank">18606952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22752315">
<a name="22752315"></a>Decoutere L, De Winter S, Vander Weyden L, et al. A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge [published correction appears in <i>Int J Clin Pharm</i>. 2012;34(5):689]. <i>Int J Clin Pharm</i>. 2012;34(5):686-688. doi:10.1007/s11096-012-9666-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22752315/pubmed" id="22752315" target="_blank">22752315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14624187">
<a name="14624187"></a>Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. <i>J Clin Psychopharmacol</i>. 2003;23(6):568-575. doi:10.1097/01.jcp.0000095342.32154.54<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/14624187/pubmed" id="14624187" target="_blank">14624187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14744166">
<a name="14744166"></a>Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. <i>J Clin Psychiatry</i>. 2004;65(1):37-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/14744166/pubmed" id="14744166" target="_blank">14744166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577402">
<a name="31577402"></a>
<i>Depression in children and young people: identification and management</i>. London: National Institute for Health and Care Excellence (UK); June 25, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31577402/pubmed" id="31577402" target="_blank">31577402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19857765">
<a name="19857765"></a>Detry O, Delwaide J, De Roover A, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. <i>Transplant Proc</i>. 2009;41(8):3435-3436. doi:10.1016/j.transproceed.2009.09.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19857765/pubmed" id="19857765" target="_blank">19857765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26660158">
<a name="26660158"></a>Dobson ET, Strawn JR. Pharmacotherapy for pediatric generalized anxiety disorder: a systematic evaluation of efficacy, safety and tolerability. <i>Paediatr Drugs</i>. 2016;18(1):45-53. doi:10.1007/s40272-015-0153-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26660158/pubmed" id="26660158" target="_blank">26660158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407896">
<a name="21407896"></a>Duggal HS, Jagadheesan K, Nizamie HS. Venlafaxine - induced orthostatic hypotension. <i>Indian J Psychiatry</i>. 2001;43(4):371-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21407896/pubmed" id="21407896" target="_blank">21407896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19099135">
<a name="19099135"></a>Dutra LA, Pedroso JL, Felix EP, Barsottini OG. Venlafaxine induced-myoclonus in a patient with mixed dementia. <i>Arq Neuropsiquiatr</i>. 2008;66(4):894-895. doi:10.1590/s0004-282x2008000600025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19099135/pubmed" id="19099135" target="_blank">19099135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EffexorXR.2018.12">
<a name="EffexorXR.2018.12"></a>Effexor XR (venlafaxine) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507636">
<a name="36507636"></a>ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S203-S215. doi:10.2337/dc23-S012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/36507636/pubmed" id="36507636" target="_blank">36507636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20478877">
<a name="20478877"></a>Emslie GJ, Mayes T, Porta G, et al. Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. <i>Am J Psychiatry</i>. 2010;167(7):782-791. doi:10.1176/appi.ajp.2010.09040552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20478877/pubmed" id="20478877" target="_blank">20478877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20207418">
<a name="20207418"></a>Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. <i>Ophthalmology</i>. 2010;117(6):1251-1255. doi:10.1016/j.ophtha.2009.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20207418/pubmed" id="20207418" target="_blank">20207418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15625158">
<a name="15625158"></a>Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. <i>Obstet Gynecol.</i> 2005;105(1):161-166. doi:10.1097/01.AOG.0000147840.06947.46<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15625158/pubmed" id="15625158" target="_blank">15625158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19708964">
<a name="19708964"></a>Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. <i>Eur J Neurol</i>. 2009;16(9):968-981. doi:10.1111/j.1468-1331.2009.02748.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19708964/pubmed" id="19708964" target="_blank">19708964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15746956">
<a name="15746956"></a>Ezra DG, Storoni M, Whitefield LA. Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment. <i>Eye (Lond)</i>. 2006;20(1):128-129. doi:10.1038/sj.eye.6701815<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15746956/pubmed" id="15746956" target="_blank">15746956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30016772">
<a name="30016772"></a>Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. <i>Psychother Psychosom</i>. 2018;87(4):195-203. doi:10.1159/000491524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30016772/pubmed" id="30016772" target="_blank">30016772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8530334">
<a name="8530334"></a>Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. <i>J Clin Psychiatry</i>. 1995;56(12):574-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/8530334/pubmed" id="8530334" target="_blank">8530334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27644102">
<a name="27644102"></a>Fernández-Ferreiro A, Pose-Reino A, Martinez-Bahamonde F, et al. Serotonin syndrome, rhabdomyolysis and convulsion associated with drug interaction between venlafaxine and amoxicillin/clavulanic acid. <i>Actas Esp Psiquiatr</i>. 2016;44(5):193-202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27644102/pubmed" id="27644102" target="_blank">27644102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17822339">
<a name="17822339"></a>Findling RL, Greenhill LL, McNamara NK, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>. 2007;17(4):433-445. doi:10.1089/cap.2007.0119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17822339/pubmed" id="17822339" target="_blank">17822339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11816261">
<a name="11816261"></a>Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. <i>Ann Pharmacother</i>. 2002;36(1):67-71. doi:10.1345/aph.1A161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11816261/pubmed" id="11816261" target="_blank">11816261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10678647">
<a name="10678647"></a>Fleisch MC, Blauer F, Gubler JG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment [published correction appears in <i>Eur Respir J.</i> 2000;15(3):627]. <i>Eur Respir J</i>. 2000;15(1):205-208. doi:10.1183/09031936.00.15120500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10678647/pubmed" id="10678647" target="_blank">10678647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11704162">
<a name="11704162"></a>Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. <i>Obstet Gynecol</i>. 2001;98(5, pt 1):737-744. doi:10.1016/s0029-7844(01)01530-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11704162/pubmed" id="11704162" target="_blank">11704162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554948">
<a name="28554948"></a>Gabriel M, Sharma V. Antidepressant discontinuation syndrome. <i>CMAJ</i>. 2017;189(21):E747. doi:10.1503/cmaj.160991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28554948/pubmed" id="28554948" target="_blank">28554948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27773479">
<a name="27773479"></a>Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. <i>Am J Kidney Dis</i>. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27773479/pubmed" id="27773479" target="_blank">27773479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193145">
<a name="22193145"></a>Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause: executive summary of recommendations. <i>Endocr Pract</i>. 2011;17(6):949-954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22193145/pubmed" id="22193145" target="_blank">22193145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34616557">
<a name="34616557"></a>Griffin H, Pearson S, Linnebur S, Fixen D. A case of venlafaxine-induced angioedema in an older adult. <i>SAGE Open Med Case Rep</i>. 2021;9:2050313X211050465. doi:10.1177/2050313X211050465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34616557/pubmed" id="34616557" target="_blank">34616557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096556">
<a name="26096556"></a>Grossman A, Messerli FH, Grossman E. Drug induced hypertension--an unappreciated cause of secondary hypertension. <i>Eur J Pharmacol</i>. 2015;763(Pt A):15-22. doi:10.1016/j.ejphar.2015.06.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26096556/pubmed" id="26096556" target="_blank">26096556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23686044">
<a name="23686044"></a>Grover S, Somaiya M, Ghormode D. Venlafaxine-associated hyponatremia presenting with catatonia. <i>J Neuropsychiatry Clin Neurosci</i>. 2013;25(2):E11-E12. doi:10.1176/appi.neuropsych.12030070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23686044/pubmed" id="23686044" target="_blank">23686044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9169969">
<a name="9169969"></a>Gupta AK, Saravay SM. Venlafaxine-induced hyponatremia. <i>J Clin Psychopharmacol</i>. 1997;17(3):223-225. doi:10.1097/00004714-199706000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9169969/pubmed" id="9169969" target="_blank">9169969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26855096">
<a name="26855096"></a>Hanley GE, Smolina K, Mintzes B, Oberlander TF, Morgan SG. Postpartum hemorrhage and use of serotonin reuptake inhibitor antidepressants in pregnancy. <i>Obstet Gynecol</i>. 2016;127(3):553-561. doi:10.1097/AOG.0000000000001200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26855096/pubmed" id="26855096" target="_blank">26855096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10807491">
<a name="10807491"></a>Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanism of action of venlafaxine. <i>Arch Gen Psychiatry</i>. 2000;57(5):503-509.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10807491/pubmed" id="10807491" target="_blank">10807491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701626">
<a name="21701626"></a>Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. <i>Drug Healthc Patient Saf</i>. 2010;2:141-150. doi:10.2147/DHPS.S7634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21701626/pubmed" id="21701626" target="_blank">21701626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/discontinuing-antidepressant-medications-in-adults?search=Discontinuing%20antidepressant%20medications%20in%20adults&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018">
<a name="Hirsch.2018"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/switching-antidepressant-medications-in-adults?search=switching%20antidepressant%20medications%20in%20adults&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10375350">
<a name="10375350"></a>Horsmans Y, De Clercq M, Sempoux C. Venlafaxine-associated hepatitis. <i>Ann Intern Med</i>. 1999;130(11):944. doi:10.7326/0003-4819-130-11-199906010-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10375350/pubmed" id="10375350" target="_blank">10375350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32075794">
<a name="32075794"></a>Huybrechts KF, Bateman BT, Pawar A, et al. Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. <i>BMJ</i>. 2020;368:m237. doi:10.1136/bmj.m237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/32075794/pubmed" id="32075794" target="_blank">32075794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30063169">
<a name="30063169"></a>Ignaszewski MJ, Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: a systematic review. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(10):668-675. doi:10.1089/cap.2017.0174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30063169/pubmed" id="30063169" target="_blank">30063169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9643618">
<a name="9643618"></a>Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. <i>Br J Clin Pharmacol</i>. 1998;45(5):459-462. doi:10.1046/j.1365-2125.1998.00710.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9643618/pubmed" id="9643618" target="_blank">9643618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11849190">
<a name="11849190"></a>Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. <i>Br J Clin Pharmacol</i>. 2002;53(1):17-22. doi:10.1046/j.0306-5251.2001.01518.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11849190/pubmed" id="11849190" target="_blank">11849190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407889">
<a name="21407889"></a>Jagadheesan K, Sandil R, Ram D. Venlafaxine-induced mania. <i>Indian J Psychiatry</i>. 2001;43(4):357-359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21407889/pubmed" id="21407889" target="_blank">21407889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27637098">
<a name="27637098"></a>Jiang HY, Xu LL, Li YC, Deng M, Peng CT, Ruan B. Antidepressant use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. <i>J Psychiatr Res</i>. 2016;83:160-167. doi:10.1016/j.jpsychires.2016.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27637098/pubmed" id="27637098" target="_blank">27637098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25969621">
<a name="25969621"></a>Jose SP. Venlafaxine-induced severe sleep bruxism in a patient with generalized anxiety disorder. <i>Indian J Psychol Med</i>. 2015;37(2):249-250. doi:10.4103/0253-7176.155679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25969621/pubmed" id="25969621" target="_blank">25969621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21726494">
<a name="21726494"></a>Jung YE, Jun TY, Kim KS, Bahk WM. Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder. <i>Int J Clin Pharmacol Ther</i>. 2011;49(7):437-443. doi:10.5414/cp201500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21726494/pubmed" id="21726494" target="_blank">21726494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413214">
<a name="18413214"></a>Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. <i>J Diabetes Complications</i>. 2008;22(4):241-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18413214/pubmed" id="18413214" target="_blank">18413214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36064232">
<a name="36064232"></a>Kameg BN, Wilson R. Venlafaxine-related galactorrhea in an adolescent female: a case report. <i>Arch Psychiatr Nurs</i>. 2022;40:106-108. doi:10.1016/j.apnu.2022.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/36064232/pubmed" id="36064232" target="_blank">36064232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28796019">
<a name="28796019"></a>Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy.<i> J Clin Psychopharmacol.</i> 2017;37(5):518-523. doi:10.1097/JCP.0000000000000751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28796019/pubmed" id="28796019" target="_blank">28796019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8784645">
<a name="8784645"></a>Kelsey JE. Dose-response relationship with venlafaxine. <i>J Clin Psychopharmacol</i>. 1996;16(3 suppl 2):21S-26S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/8784645/pubmed" id="8784645" target="_blank">8784645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10830148">
<a name="10830148"></a>Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. <i>J Clin Psychiatry</i>. 2000;61(4):276-281. doi:10.4088/jcp.v61n0406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10830148/pubmed" id="10830148" target="_blank">10830148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30817861">
<a name="30817861"></a>Khan S, Sivananthan M, Bacon O. Serotonin sensitivity and withdrawal with low-dose venlafaxine. <i>Prim Care Companion CNS Disord</i>. 2019;21(1):18l02334. doi:10.4088/PCC.18l02334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30817861/pubmed" id="30817861" target="_blank">30817861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14656626">
<a name="14656626"></a>Khurana RN, Baudendistel TE. Hypertensive crisis associated with venlafaxine. <i>Am J Med</i>. 2003;115(8):676-677. doi:10.1016/s0002-9343(03)00472-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/14656626/pubmed" id="14656626" target="_blank">14656626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11921151">
<a name="11921151"></a>Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. <i>Int J Geriatr Psychiatry</i>. 2002;17(3):231-237. doi:10.1002/gps.591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11921151/pubmed" id="11921151" target="_blank">11921151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18004149">
<a name="18004149"></a>Klier CM, Mossaheb N, Saria A, et al, "Pharmacokinetics and Elimination of Quetiapine, Venlafaxine, and Trazodone During Pregnancy and Postpartum,"<i> J Clin Psychopharmacol</i>, 2007, 27(6):720-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18004149/pubmed" id="18004149" target="_blank">18004149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9040933">
<a name="9040933"></a>Kohn S, Labbate LA. Venlafaxine and ecchymosis. <i>Can J Psychiatry</i>. 1997;42(1):91. doi:10.1177/070674379704200126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9040933/pubmed" id="9040933" target="_blank">9040933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849776">
<a name="17849776"></a>Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry</i>. 2007;164(7)(suppl):5-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17849776/pubmed" id="17849776" target="_blank">17849776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37160238">
<a name="37160238"></a>Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents. <i>Int J Antimicrob Agents.</i> 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/37160238/pubmed" id="37160238" target="_blank">37160238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28976215">
<a name="28976215"></a>Kwok CSN, Lim LEC. Mania following antidepressant discontinuation in depression: two case reports. <i>Australas Psychiatry</i>. 2017;25(6):617-621. doi:10.1177/1039856217732470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28976215/pubmed" id="28976215" target="_blank">28976215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21772780">
<a name="21772780"></a>Lahon K, Shetty HM, Paramel A, Sharma G. Sexual dysfunction with the use of antidepressants in a tertiary care mental health setting - a retrospective case series. <i>J Pharmacol Pharmacother</i>. 2011;2(2):128-131. doi:10.4103/0976-500X.81913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21772780/pubmed" id="21772780" target="_blank">21772780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28383363">
<a name="28383363"></a>Leong C, Alessi-Severini S, Enns MW, et al. Cerebrovascular, cardiovascular, and mortality events in new users of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors: a propensity score-matched population-based study. <i>J Clin Psychopharmacol</i>. 2017;37(3):332-340. doi:10.1097/JCP.0000000000000701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28383363/pubmed" id="28383363" target="_blank">28383363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27194321">
<a name="27194321"></a>Leth-Møller KB, Hansen AH, Torstensson M, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. <i>BMJ Open</i>. 2016;6(5):e011200. doi:10.1136/bmjopen-2016-011200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27194321/pubmed" id="27194321" target="_blank">27194321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18188866">
<a name="18188866"></a>Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. doi:10.1002/pds.1546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18188866/pubmed" id="18188866" target="_blank">18188866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15699296">
<a name="15699296"></a>Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. <i>Arch Gen Psychiatry</i>. 2005;62(2):190-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15699296/pubmed" id="15699296" target="_blank">15699296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12013367">
<a name="12013367"></a>Linnebur SA, Saseen JJ, Pace WD. Venlafaxine-associated vaginal bleeding. <i>Pharmacotherapy</i>. 2002;22(5):652-655. doi:10.1592/phco.22.8.652.33219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12013367/pubmed" id="12013367" target="_blank">12013367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17229772">
<a name="17229772"></a>Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study. <i>Ann Oncol</i>. 2007;18(4):689-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17229772/pubmed" id="17229772" target="_blank">17229772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11145492">
<a name="11145492"></a>Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. <i>Lancet.</i> 2000;356(9247):2059-2063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11145492/pubmed" id="11145492" target="_blank">11145492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16505409">
<a name="16505409"></a>Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group trial N99C7. <i>J Clin Oncol</i>. 2006;24(9):1409-1414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16505409/pubmed" id="16505409" target="_blank">16505409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9475820">
<a name="9475820"></a>Masood GR, Karki SD, Patterson WR. Hyponatremia with venlafaxine. <i>Ann Pharmacother</i>. 1998;32(1):49-51. doi:10.1345/aph.17117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9475820/pubmed" id="9475820" target="_blank">9475820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31635997">
<a name="31635997"></a>Mawardi G, Markman TM, Muslem R, et al. SSRI/SNRI therapy is associated with a higher risk of gastrointestinal bleeding in LVAD patients. <i>Heart Lung Circ</i>. 2019;S1443-9506(19)31374-5. doi:10.1016/j.hlc.2019.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31635997/pubmed" id="31635997" target="_blank">31635997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9232089">
<a name="9232089"></a>Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP. Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine. <i>Neth J Med</i>. 1997;50(6):243-245. doi:10.1016/s0300-2977(97)00005-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9232089/pubmed" id="9232089" target="_blank">9232089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15883980">
<a name="15883980"></a>Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. <i>Pharmacoepidemiol Drug Saf</i>. 2005;14(6):367-372. doi:10.1002/pds.1095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15883980/pubmed" id="15883980" target="_blank">15883980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16974194">
<a name="16974194"></a>Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. <i>J Clin Psychopharmacol.</i> 2006;26(5):508-511. doi:10.1097/01.jcp.0000236656.70544.f3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16974194/pubmed" id="16974194" target="_blank">16974194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11229449">
<a name="11229449"></a>Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. <i>J Clin Psychiatry</i>. 2001;62 Suppl 3:10-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11229449/pubmed" id="11229449" target="_blank">11229449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24566587">
<a name="24566587"></a>Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). <i>Osteoporos Int</i>. 2014;25(5):1473-1481. doi:10.1007/s00198-014-2649-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24566587/pubmed" id="24566587" target="_blank">24566587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397569">
<a name="30397569"></a>Mullen S. Major depressive disorder in children and adolescents. <i>Ment Health Clin</i>. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30397569/pubmed" id="30397569" target="_blank">30397569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25943730">
<a name="25943730"></a>Murphy RM, Bakir B, O'Brien C, Wiggs JL, Pasquale LR. Drug-induced bilateral secondary angle-closure glaucoma: a literature synthesis. <i>J Glaucoma</i>. 2016;25(2):e99-e105. doi:10.1097/IJG.0000000000000270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25943730/pubmed" id="25943730" target="_blank">25943730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655517">
<a name="17655517"></a>Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. <i>Pharmacotherapy</i>. 2007;27(8):1189-1197. doi:10.1592/phco.27.8.1189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17655517/pubmed" id="17655517" target="_blank">17655517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE clinical guideline NG87. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87/chapter/recommendations. Published March 14, 2018a. Accessed January 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder (update). NICE clinical guideline NG87. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87/evidence/c-pharmacological-efficacy-and-sequencing-pdf-4783686303. Published March 2018b. Accessed January 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.3">
<a name="NICE.3"></a>National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management. NICE clinical guideline NG134. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng134. Published June 25, 2019. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia.<i> J Am Geriatr Soc</i>. 2011;59(4):577-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health</i>. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19607765">
<a name="19607765"></a>Newport DJ, Ritchie JC, Knight BT, et al. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. <i>J Clin Psychiatry</i>. 2009;70(9):1304-1310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19607765/pubmed" id="19607765" target="_blank">19607765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11999245">
<a name="11999245"></a>Ng B, Sanbrook GM, Malouf AJ, Agarwal SA. Venlafaxine and bilateral acute angle closure glaucoma. <i>Med J Aust</i>. 2002;176(5):241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/11999245/pubmed" id="11999245" target="_blank">11999245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19337457">
<a name="19337457"></a>Norman TR, Olver JS. Duloxetine in the treatment of generalized anxiety disorder. <i>Neuropsychiatr Dis Treat</i>. 2008;4(6):1169-1180. doi:10.2147/ndt.s2820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19337457/pubmed" id="19337457" target="_blank">19337457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26382310">
<a name="26382310"></a>North American Menopause Society (NAMS). Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. <i>Menopause.</i> 2015;22(11):1155-1172. doi:10.1097/GME.0000000000000546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26382310/pubmed" id="26382310" target="_blank">26382310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37252752">
<a name="37252752"></a>North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/37252752/pubmed" id="37252752" target="_blank">37252752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15361923">
<a name="15361923"></a>O'Bryan EC 3rd, Albanese RP. A case report of fluoxetine- and venlafaxine-induced hair loss. <i>Prim Care Companion J Clin Psychiatry</i>. 2004;6(4):181. doi:10.4088/pcc.v06n0407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15361923/pubmed" id="15361923" target="_blank">15361923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25237379">
<a name="25237379"></a>Oh S, Cha SI, Kim H, et al. A case of venlafaxine-induced interstitial lung disease. <i>Tuberc Respir Dis (Seoul)</i>. 2014;77(2):81-84. doi:10.4046/trd.2014.77.2.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25237379/pubmed" id="25237379" target="_blank">25237379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9231317">
<a name="9231317"></a>Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>J Child Adolesc Psychopharmacol.</i> 1996;6(4):241-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9231317/pubmed" id="9231317" target="_blank">9231317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31688406">
<a name="31688406"></a>Osuagwu FC, Bradley R. Delayed sinus tachycardia associated with venlafaxine administration: a unique case report and discussion. <i>J Clin Psychopharmacol</i>. 2019;39(6):689-690. doi:10.1097/JCP.0000000000001140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31688406/pubmed" id="31688406" target="_blank">31688406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15705120">
<a name="15705120"></a>Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. <i>Headache</i>. 2005;45(2):144-152. doi:10.1111/j.1526-4610.2005.05029.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15705120/pubmed" id="15705120" target="_blank">15705120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34802219">
<a name="34802219"></a>Özdemir S. A case report of rare adverse events associated with venlafaxine administration: hypoglycemia and lactic acidosis. <i>Korean J Fam Med</i>. 2022;43(1):83-85. doi:10.4082/kjfm.20.0100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34802219/pubmed" id="34802219" target="_blank">34802219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23965506">
<a name="23965506"></a>Palmsten K, Hernández-Díaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. <i>BMJ</i>. 2013;347:f4877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23965506/pubmed" id="23965506" target="_blank">23965506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12549949">
<a name="12549949"></a>Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. <i>Ann Pharmacother</i>. 2003;37(2):209-211. doi:10.1177/106002800303700209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/12549949/pubmed" id="12549949" target="_blank">12549949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24758982">
<a name="24758982"></a>Panganiban B, Kinder B, Litner J. A painful urologic emergency. <i>JAAPA</i>. 2014;27(5):54-55. doi:10.1097/01.JAA.0000446226.77930.5f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24758982/pubmed" id="24758982" target="_blank">24758982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407890">
<a name="21407890"></a>Pardal PK, John TR, Rathee SP. Venlafaxine induced hypertension:a case report. <i>Indian J Psychiatry</i>. 2001;43(4):360-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21407890/pubmed" id="21407890" target="_blank">21407890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23914755">
<a name="23914755"></a>Park SH, Ishino R. Liver injury associated with antidepressants. <i>Curr Drug Saf</i>. 2013;8(3):207-223. doi:10.2174/1574886311308030011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23914755/pubmed" id="23914755" target="_blank">23914755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24153222">
<a name="24153222"></a>Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?. <i>J Pharm Pract</i>. 2014;27(1):71-78. doi:10.1177/0897190013504957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24153222/pubmed" id="24153222" target="_blank">24153222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31371035">
<a name="31371035"></a>Perrotta C, Giordano F, Colombo A, et al. Postpartum bleeding in pregnant women receiving SSRIs/SNRIs: new insights from a descriptive observational study and an analysis of data from the FAERS database. <i>Clin Ther</i>. 2019;41(9):1755-1766. doi:10.1016/j.clinthera.2019.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31371035/pubmed" id="31371035" target="_blank">31371035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24399428">
<a name="24399428"></a>Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. <i>Am J Psychiatry</i>. 2014;171(1):44-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24399428/pubmed" id="24399428" target="_blank">24399428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999003">
<a name="27999003"></a>Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2017;40(1):136-154. doi:10.2337/dc16-2042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27999003/pubmed" id="27999003" target="_blank">27999003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34965987">
<a name="34965987"></a>Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. <i>Neurology</i>. 2022;98(1):31-43. doi:10.1212/WNL.0000000000013038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34965987/pubmed" id="34965987" target="_blank">34965987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2)(suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814334">
<a name="20814334"></a>Rajapakse S, Abeynaike L, Wickramarathne T. Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease. <i>J Clin Psychopharmacol</i>. 2010;30(5):620-622. doi:10.1097/JCP.0b013e3181ee2ae7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20814334/pubmed" id="20814334" target="_blank">20814334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19452377">
<a name="19452377"></a>Rampono J, Simmer K, Ilett KF, et al, "Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate," <i>Pharmacopsychiatry</i>, 2009, 42(3):95-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19452377/pubmed" id="19452377" target="_blank">19452377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26032210">
<a name="26032210"></a>Rauma PH, Pasco JA, Berk M, et al. The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men. <i>J Musculoskelet Neuronal Interact</i>. 2015;15(2):177-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26032210/pubmed" id="26032210" target="_blank">26032210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047705">
<a name="20047705"></a>Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. <i>Psychol Med</i>. 2010;40(10):1723-1733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20047705/pubmed" id="20047705" target="_blank">20047705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17189754">
<a name="17189754"></a>Romero S, Pintor L, Serra M, et al. Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. <i>Gen Hosp Psychiatry</i>. 2007;29(1):81-84. doi:10.1016/j.genhosppsych.2006.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17189754/pubmed" id="17189754" target="_blank">17189754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288411">
<a name="15288411"></a>Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study [published correction appears in <i>Pain</i>. 2005;113(1-2):248]. <i>Pain</i>. 2004;110(3):697-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15288411/pubmed" id="15288411" target="_blank">15288411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24284851">
<a name="24284851"></a>Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis [published correction appears in <i>Pain Physician</i>. 2014;17(2):203]. <i>Pain Physician</i>. 2013;16(6):E705-E714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24284851/pubmed" id="24284851" target="_blank">24284851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26644543">
<a name="26644543"></a>Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. <i>J Clin Oncol</i>. 2016;34(6):611-635. doi:10.1200/JCO.2015.64.3809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26644543/pubmed" id="26644543" target="_blank">26644543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267793">
<a name="17267793"></a>Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. <i>Am J Psychiatry</i>. 2007;164(2):290-300. doi:10.1176/ajp.2007.164.2.290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17267793/pubmed" id="17267793" target="_blank">17267793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21448114">
<a name="21448114"></a>Sabljić V, Ružić K, Rakun R. Venlafaxine withdrawal syndrome. <i>Psychiatr Danub</i>. 2011;23(1):117-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/21448114/pubmed" id="21448114" target="_blank">21448114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18211302">
<a name="18211302"></a>Safarinejad MR. Safety and efficacy of venlafaxine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. <i>Andrologia</i>. 2008;40(1):49-55. doi:10.1111/j.1439-0272.2008.00813.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18211302/pubmed" id="18211302" target="_blank">18211302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34540303">
<a name="34540303"></a>Sakurada K, Nibuya M, Yamada K, Nakagawa S, Suzuki E. Kleptomania induced by venlafaxine. <i>Case Rep Psychiatry</i>. 2021;2021:8470045. doi:10.1155/2021/8470045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34540303/pubmed" id="34540303" target="_blank">34540303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10638063">
<a name="10638063"></a>Samuel RZ. Priapism associated with venlafaxine use. <i>J Am Acad Child Adolesc Psychiatry</i>. 2000;39(1):16-17. doi:10.1097/00004583-200001000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10638063/pubmed" id="10638063" target="_blank">10638063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32267090">
<a name="32267090"></a>Sato S, Sodeyama N, Matsuzaki A, Shiratori Y. Apathy symptoms induced by low-dose venlafaxine: Two cases. <i>Neuropsychopharmacol Rep</i>. 2020;40(2):196-197. doi:10.1002/npr2.12104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/32267090/pubmed" id="32267090" target="_blank">32267090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scammell.2019">
<a name="Scammell.2019"></a>Scammell TE. Treatment of narcolepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/treatment-of-narcolepsy-in-adults?search=treatment%20of%20narcolepsy&amp;source=search_result&amp;selectedTitle=1~117&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31165430">
<a name="31165430"></a>Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case-control study. <i>Drug Saf</i>. 2019;42(9):1081-1089. doi:10.1007/s40264-019-00837-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31165430/pubmed" id="31165430" target="_blank">31165430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30116895">
<a name="30116895"></a>Schoretsanitis G, Augustin M, Saßmannshausen H, Franz C, Gründer G, Paulzen M. Antidepressants in breast milk; comparative analysis of excretion ratios. <i>Arch Womens Ment Health</i>. 2019;22(3):383-390. doi:10.1007/s00737-018-0905-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30116895/pubmed" id="30116895" target="_blank">30116895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26491599">
<a name="26491599"></a>Selvaraj V, Gunasekar P, Kumar S, Alsakaf I. Urinary incontinence due to overactive detrusor muscle: a rare side effect of venlafaxine. <i>Case Rep Urol</i>. 2015;2015:690931. doi:10.1155/2015/690931<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26491599/pubmed" id="26491599" target="_blank">26491599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14742779">
<a name="14742779"></a>Sencan I, Sahin I, Ozcetin A. Low-dose venlafaxine-associated liver toxicity in chronic hepatitis. <i>Ann Pharmacother</i>. 2004;38(2):352-353. doi:10.1345/aph.1D205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/14742779/pubmed" id="14742779" target="_blank">14742779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19440080">
<a name="19440080"></a>Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>J Clin Psychopharmacol.</i> 2009;29(3):259-66. doi:10.1097/JCP.0b013e3181a5233f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19440080/pubmed" id="19440080" target="_blank">19440080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22892234">
<a name="22892234"></a>Sevastru S, Wakatsuki M, Fennell J, Grocott MP. Plasma exchange in the management of a case of hypertriglyceridaemic pancreatitis triggered by venlafaxine. <i>BMJ Case Rep</i>. 2012;2012:bcr1120115208. doi:10.1136/bcr.11.2011.5208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22892234/pubmed" id="22892234" target="_blank">22892234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26819231">
<a name="26819231"></a>Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. <i>BMJ</i>. 2016;352:i65. doi:10.1136/bmj.i65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26819231/pubmed" id="26819231" target="_blank">26819231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23358607">
<a name="23358607"></a>Shea ML, Garfield LD, Teitelbaum S, et al. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption. <i>Osteoporos Int</i>. 2013;24(5):1741-1749. doi:10.1007/s00198-012-2170-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23358607/pubmed" id="23358607" target="_blank">23358607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton, RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30008467">
<a name="30008467"></a>Smischney NJ, Pollard EM, Nookala AU, Olatoye OO. Serotonin syndrome in the perioperative setting. <i>Am J Case Rep</i>. 2018;19:833-835. doi:10.12659/AJCR.909497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30008467/pubmed" id="30008467" target="_blank">30008467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30964616">
<a name="30964616"></a>Sobieraj DM, Baker WL, Martinez BK, et al. <i>Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults</i>. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30964616/pubmed" id="30964616" target="_blank">30964616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23073329">
<a name="23073329"></a>Stadlmann S, Portmann S, Tschopp S, Terracciano LM. Venlafaxine-induced cholestatic hepatitis: case report and review of literature. <i>Am J Surg Pathol</i>. 2012;36(11):1724-1728. doi:10.1097/PAS.0b013e31826af296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/23073329/pubmed" id="23073329" target="_blank">23073329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2018">
<a name="Stein.2018"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/pharmacotherapy-for-social-anxiety-disorder-in-adults?search=Pharmacotherapy%20for%20social%20anxiety%20disorder%20in%20adults&amp;source=search_result&amp;selectedTitle=1~119&amp;usage_type=default&amp;display_rank=1" target="_blank">http://www.uptodate.com</a>. Accessed August 6, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15258718">
<a name="15258718"></a>Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. <i>Psychopharmacology</i>
<i>(Berl)</i>. 2005;177(3):280-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/15258718/pubmed" id="15258718" target="_blank">15258718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25449861">
<a name="25449861"></a>Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. <i>Depress Anxiety</i>. 2015;32(3):149-157. doi:10.1002/da.22329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/25449861/pubmed" id="25449861" target="_blank">25449861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19667978">
<a name="19667978"></a>Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. <i>Clin Neuropharmacol</i>. 2009;32(5):254-258. doi:10.1097/WNF.0b013e3181a8c84f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19667978/pubmed" id="19667978" target="_blank">19667978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779744">
<a name="16779744"></a>Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis.</i> 2006;43(2):180-187. doi:10.1086/504809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16779744/pubmed" id="16779744" target="_blank">16779744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24989434">
<a name="24989434"></a>ter Horst PG, Larmené-Beld KH, Bosman J, van der Veen EL, Wieringa A, Smit JP. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. <i>J Clin Pharm Ther</i>. 2014;39(5):541-544.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24989434/pubmed" id="24989434" target="_blank">24989434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9818630">
<a name="9818630"></a>Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. <i>J Clin Psychiatry</i>. 1998;59(10):502-508. doi:10.4088/jcp.v59n1002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9818630/pubmed" id="9818630" target="_blank">9818630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8033490">
<a name="8033490"></a>Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. <i>Clin Pharmacol Ther</i>. 1994;56(1):14-21. doi:10.1038/clpt.1994.95<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/8033490/pubmed" id="8033490" target="_blank">8033490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22285303">
<a name="22285303"></a>Tully PJ, Cardinal T, Bennetts JS, Baker RA. Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft surgery. <i>Heart Lung Circ</i>. 2012;21(4):206-214. doi:10.1016/j.hlc.2011.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/22285303/pubmed" id="22285303" target="_blank">22285303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34000145">
<a name="34000145"></a>Tuman TC. Venlafaxine-induced urinary retention. <i>Prim Care Companion CNS Disord</i>. 2021;23(1):20l02702. doi:10.4088/PCC.20l02702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/34000145/pubmed" id="34000145" target="_blank">34000145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USVADoD.2017">
<a name="USVADoD.2017"></a>US Department of Veterans Affairs/Department of Defense. VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal082917.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal082917.pdf</a>. Published June 2017. Accessed December 6, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35960894">
<a name="35960894"></a>Uvais NA, Moideen S. A case of acute heart failure probably associated with venlafaxine use. <i>Prim Care Companion CNS Disord</i>. 2022;24(4):21cr02908. doi:10.4088/PCC.21cr02908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/35960894/pubmed" id="35960894" target="_blank">35960894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583240">
<a name="27583240"></a>Vasudev R, Rampal U, Patel H, Patel K, Bikkina M, Shamoon F. Selective serotonin-norepinephrine reuptake inhibitors-induced takotsubo cardiomyopathy. <i>N Am J Med Sci</i>. 2016;8(7):312-315. doi:10.4103/1947-2714.187153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/27583240/pubmed" id="27583240" target="_blank">27583240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Almatica.1">
<a name="Almatica.1"></a>Venlafaxine besylate extended-release tablets [prescribing information]. Morristown, NJ: Almatica Pharma LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BluePoint.1">
<a name="BluePoint.1"></a>Venlafaxine tablets, USP [prescribing information]. Ahmedabad, India: BluePoint Laboratories; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Venlafaxine.2020.06">
<a name="Venlafaxine.2020.06"></a>Venlafaxine tablets, USP [prescribing information]. East Brunswick, NJ: Avet Pharmaceutials Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VenlafaxineER.2018.01">
<a name="VenlafaxineER.2018.01"></a>Venlafaxine hydrochloride extended-release tablets [prescribing information]. Alpharetta, GA: Vertical Pharmaceuticals LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8468312">
<a name="8468312"></a>Venlafaxine: A New Dimension in Antidepressant Pharmacotherapy. <i>J Clin Psychiatry.</i> 1993;54(3):119-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/8468312/pubmed" id="8468312" target="_blank">8468312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26975593">
<a name="26975593"></a>Viramontes TS, Truong H, Linnebur SA. Antidepressant-induced hyponatremia in older adults. <i>Consult Pharm</i>. 2016;31(3):139-150. doi:10.4140/TCP.n.2016.139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26975593/pubmed" id="26975593" target="_blank">26975593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24362450">
<a name="24362450"></a>Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. <i>Am J Psychiatry</i>. 2014;171(4):404-415. doi:10.1176/appi.ajp.2013.13050709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24362450/pubmed" id="24362450" target="_blank">24362450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26126579">
<a name="26126579"></a>Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. <i>Osteoporos Int</i>. 2016;27(1):57-63. doi:10.1007/s00198-015-3213-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26126579/pubmed" id="26126579" target="_blank">26126579</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Wang Z, Whiteside S, Sim L, et al. Anxiety in Children. Comparative Effectiveness Review No. 192. (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I.) AHRQ Publication No. 17-EHC023-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2017. Erratum July 2018. doi:10.23970/AHRQEPCCER192</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24022904">
<a name="24022904"></a>Weiler S, Offinger A, Exadaktylos AK. Shaking head means "no". <i>BMJ Case Rep</i>. 2013;2013:bcr2013200796. doi:10.1136/bcr-2013-200796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24022904/pubmed" id="24022904" target="_blank">24022904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24022904">
<a name="24022904"></a>Weissman AM, Wisner KL, Perel JM, et al. Venlafaxine levels in lactating mothers, breast milk, and nursing infants. Abstracts of the 31st Annual Meeting of the North American Society for Psychosocial Obstetrics and Gynecology. February 19-22, 2003, Lihue, Hawaii, USA. <i>Arch Womens Ment Health</i>. 2003;6(suppl 1):S20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/24022904/pubmed" id="24022904" target="_blank">24022904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17087787">
<a name="17087787"></a>Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction [published correction appears in <i>Acta Psychiatr Scand</i>. 2007;115(3):255]. <i>Acta Psychiatr Scand</i>. 2006;114(6):384-397. doi:10.1111/j.1600-0447.2006.00890.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/17087787/pubmed" id="17087787" target="_blank">17087787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708853">
<a name="28708853"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition. <i>PLoS One</i>. 2017;12(7):e0181082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/28708853/pubmed" id="28708853" target="_blank">28708853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30278181">
<a name="30278181"></a>Wiciński M, Kaluzny BJ, Liberski S, Marczak D, Seredyka-Burduk M, Pawlak-Osińska K. Association between serotonin-norepinephrine reuptake inhibitors and acute angle closure: What is known?. <i>Surv Ophthalmol</i>. 2019;64(2):185-194. doi:10.1016/j.survophthal.2018.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/30278181/pubmed" id="30278181" target="_blank">30278181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19694628">
<a name="19694628"></a>Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. <i>Acta Psychiatr Scand</i>. 2010;121(3):190-200. doi:10.1111/j.1600-0447.2009.01464.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19694628/pubmed" id="19694628" target="_blank">19694628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31570648">
<a name="31570648"></a>Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2019;144(4):e20192528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/31570648/pubmed" id="31570648" target="_blank">31570648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18029426">
<a name="18029426"></a>Yavasoglu I, Kadikoylu G, Bolaman Z. Gingival bleeding due to venlafaxine. <i>Ann Pharmacother</i>. 2008;42(1):144-145. doi:10.1345/aph.1K180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/18029426/pubmed" id="18029426" target="_blank">18029426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19841512">
<a name="19841512"></a>Yildirim B, Tuncer C, Ergun M, Unal S. Venlafaxine-induced hepatotoxicity in a patient with ulcerative colitis. <i>Ann Hepatol</i>. 2009;8(3):271-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/19841512/pubmed" id="19841512" target="_blank">19841512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26264066">
<a name="26264066"></a>Young JB, Singh TD, Rabinstein AA, Fugate JE. SSRI/SNRI use is not associated with increased risk of delayed cerebral ischemia after aSAH. <i>Neurocrit Care</i>. 2016;24(2):197-201. doi:10.1007/s12028-015-0190-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/26264066/pubmed" id="26264066" target="_blank">26264066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20860068">
<a name="20860068"></a>Zarinara AR, Mohammadi MR, Hazrati N, et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. <i>Hum Psychopharmacol</i>. 2010;25(7-8):530-535. doi:10.1002/hup.1148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/20860068/pubmed" id="20860068" target="_blank">20860068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29893371">
<a name="29893371"></a>Zhou N, Zhao JX, Zhu YN, Zhang P, Zuo Y. Acute angle-closure glaucoma caused by venlafaxine. <i>Chin Med J (Engl)</i>. 2018;131(12):1502-1503. doi:10.4103/0366-6999.233952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/29893371/pubmed" id="29893371" target="_blank">29893371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9565731">
<a name="9565731"></a>Zimmer B, Kant R, Zeiler D, Brilmyer M. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. <i>Int J Psychiatry Med</i>. 1997;27(4):353-364. doi:10.2190/UDRD-99CB-T6KH-EDKP<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/venlafaxine-drug-information/abstract-text/9565731/pubmed" id="9565731" target="_blank">9565731</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10042 Version 771.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
